THE JOURNAL OF IMMUNOLOGY
Copyright © 1983 by The American Association of Immunologists
Vol. 131, No. 6, December 1983
Printed in U.S.A.

AUTHOR INDEX TO VOLUME 131

Abbas, Abul K., 1728
Abdel-Hafez, S. K., 1475
Abe, Ryo, 1646
Abo, Toru, 1822
Abrahams, I. Willard, 259
Abrams, Paul G., 1201
Ackerman, S. J., 2977
Adachi, Mitsunobu, 303, 1246
Adamowski, C., 2930
Adams, Dolph O., 1038, 2086
Adams, P. H., 2908
Adkinson, N. Franklin, Jr., 1936
Aglietta, Massimo, 2397
Ahmed, Parveen, 2458
Akiyama, Mitoshi, 175, 3085
Albini, B., 3021
Albino, Anthony P., 1595
Alexander, N. J., 2908
Allen, P. M., 2919
Altman, Amnon, 826
Alves, César Andrade, 972
Amento, Edward P., 743
Anderson, D. J., 2908
Anderson, Donna M., 1900
Anderson, Kenneth C., 244
Anderson, Sarah, 1616
Andreani, Marco, 2050
Andres, Giuseppe, 1802
Andrysiak, Patricia M., 1650
Antell, Laura, 1626
Appella, Ettore, 319
Arai, Sumio, 651
Araujo, Fausto G., 977
Archibald, Anna C., 207
Argilan, Fred, 132
Arnaout, M. Amin, 439
Arner, Leslie S., 2210
Arnold, Larry W., 2064
Aronson, R. A., 2796
Ascher, Nancy L., 617
Ashkar, Samy, 869
Askenase, P. W., 2675, 2687
Asofsky, Richard, 98
Atkins, Fred M., 1420
Atkinson, Kerry, 1771
Auerbach, Harvey S., 2420
August, J. Thomas, 1882
Ault, Kenneth A., 1178
Aune, Thomas M., 2301, 2848
Auriault, Claude, 464
Austen, K. F., 2958
Avrameas, Stratis, 2267
Ayala, Eleanor, 1
Azogui, Orly, 1205

Babcock, George F., 1789
Bach, Fritz H., 1318, 1622, 1670, 1676, 2135
Bach, Mark A., 365
Badger, Alison M., 1626
Bagot, M., 2735
Baird, S., 1576
Baird, S. M., 3073
Baker, Patricia J., 2484
Bakker, Roland H. J., 1234
Bakouche, Ouahid, 485
Balazs, I., 2821
Balch, Charles M., 1822
Ball, Edward J., 666
Balow, James E., 1797
Banda, Diane, 397
Barbarulli, Giordano, 1707
Barber, John, 1554
Barisas, B. G., 2924
Barlozzari, Teresa, 1024
Barnett, Eugene V., 217
Baron, Samuel, 1554
Barry, Wanda C., 70
Bartalini, Marcela, 1707
Bates, Michael, 244
Battye, F. L., 2983
Batuman, O. A., 533
Baum, L., 2930
Baxevanis, Constantin N., 628
Bazin, Herve, 1475
Bean, M. A., 3085
Bean, Michael A., 175
Beatty, Patrick G., 180, 2404, 2913
Beer, Dennis J., 1854
Behar, Samuel, 762
Behforouz, Nancy, 2576
Bell, M. K., 1698
Benacerraf, Baruj, 30, 2184
Bender, Paul E., 1626
Bender, T. P., 2882
Benike, Claudia J., 158
Benjamin, William R., 265
Benjamini, Eli, 561, 567, 2875
Benner, Robbert, 1629
Bennett, Michael, 2101, 2699
Bennink, Jack R., 471
Ben-Nun, A., 2810
Benson, Herbert, 1178
Bentley, Anna G., 1466
Berger, Melvin, 899
Bergman, Yehudit, 1876
Berke, Gideon, 50
Berliner, Judith A., 2368
Berman, Jeffrey S., 1854
Bernabeu, Carmelo, 2032
Bertoglio, Jacques H., 2279
Berzins, Klavs, 2000
Bevan, Michael J., 794
Bhogal, B. S., 2254
Biasi, Giovanni, 16
Bibro, Mary, 497
Bick, P. H., 2623
Biddison, William E., 152
Biggs, James C., 1771
Bikoff, Elizabeth, 103
Billings, Peter B., 347
Bindon, C., 2837
Binkley, Francis, 869
Biro, P. Andrew, 2032
Biron, Christine A., 991, 1539
Bishop, Gail A., 1849
Bishop, Nancy H., 1973
Bialock, J. Edwin, 1895
Bland, Catherine E., 915
Blattner, William A., 2021
Bloom, Marshall E., 1558
Bluestein, Harry G., 768
Blum, Arthur M., 2529
Blumenthal, Elliott, 794
Bocchieri, M. H., 533
Bona, Constantin A., 103
Bonagura, V., 2890
Bonavida, Benjamin, 1426
Bont, Willy S., 201
Booth, Roger J., 1289
Boraschi, Diana, 1707
Borel, Yves, 1762, 2204
Boros, Dov L., 959
Bortin, Mortimer M., 2050
Borysenko, Myrin, 1178
Bottero, Lisabianca, 1882
Boyer, Brigitte, 1339
Braley-Mullen, Helen, 2190
Brankovan, Vera, 175, 3085
Bratescu, Aurel, 1189
Braun, Marcus P., 180
Breathnach, S. M., 2741
Brentjens, Jan, 1802
Brestel, Eric P., 2515
Bretscher, Peter A., 1103
Brewster, Douglas R., 1613
Brewster, Marge A., 1011
Brickman, Chaim M., 1240
Britvan, L., 2705, 2710
Broder, Samuel, 725
Bron, C., 3091
Brooks, Colin G., 288, 1391, 2386
Brown, Alan R., 423
Brown, Eric J., 403, 409, 1443
Brown, Lawrence R., 165
Brown, Robert E., 1011
Brown, Thomas R., 1252
Broxmeyer, Hal E., 1300
Brunet, Gunter, 434
Brusdeilins, Martin, 2427
Bukowski, Jack F., 991, 1531
Bullock, W. E., 984
Burakoff, Steven J., 611, 1182, 1312, 2777
Burchell, Joy, 508
Burger, Reinhard, 1350
Burgess, A. W., 2983
Burowsky, Daphna, 1600
Burrichter, Heinz, 1591
Burton, Robert C., 1391
Bussolino, Federico, 1802, 2397
Buszello, Heinz, 548
Butler, Joseph L., 801
Butler, Larry D., 77, 1663
Butler-Browne, Gillian S., 2267

Cain, Charles A., 622
Caldwell, Peter R., 1802
Callard, Robin E., 1229
Calvert, Jane E., 1693
Cambier, J. C., 2641
Camussi, Giovanni, 1802, 2397
Capel, Peter J. A., 86
Capron, Andre, 464, 1475
Capron, Monique, 464, 1466, 1475
Carbone, Amy M., 1263
Carey, Gregory D., 1368
Carney, Desmond N., 497
Carpén, O., 2695
Carpenter, Charles B., 1065
Carpenter, Karen, 1754
Carrasco, Luis, 783
Carroll, Peter G., 1007
Carson, Dennis A., 719, 1776
Carter, Richard, 2557
Carter, W. H., 2623
Castles, James J., 2069
Censini, Stefano, 1707
Center, David M., 1854
Ceredig, Rhodri, 1085
Cerny, Jan, 2576
Cesari, Italo M., 464
Chan, C., 2868
Chang, Cecile C., 1318
Chang, Z., 2821
Charley, Michael R., 2101
Charon, J. A., 816
Charron, Dominique J., 1339
Chedid, Louis, 1492
Chen, Benjamin P. P., 57
Chen, Sally, 617
Chen, Y.-W., 3049
Chervenak, Robert, 1688
Chesnut, Robert W., 23, 109
Cheung, Kee, 207
Cheung, Roy K., 2291
Chia, David, 217
Chieco-Bianchi, Luigi, 16
Chiller, Jacques M., 23, 1663
Chin, Yee-Hon, 1368
Chiu, P., 3073
Chused, Thomas M., 1257, 2789
Ciampi, Antonio, 1115
Cibull, Michael L., 195
Cigen, Ragnhild, 1344
Claflin, J. L., 2882
Claman, H. N., 2682
Clark, David A., 540, 638
Clarke, Gregory, 1201
Clark-Lewis, Ian, 788
Clayberger, C., 2777
Clement, Loran T., 1214, 2757
Coe, John E., 1558
Coffman, Robert L., 64
Cohen, David J., 1065
Cohen, Irun R., 2316, 2810
Cohen, J. H. M., 2767
Cohen, J. John, 1688
Cohen, Leonard, 378
Cohn, Melvin, 1154
Coico, R. F., 2254
Cole, Barry C., 543, 1702, 2392
Coleman, Mary Sue, 195
Collavo, Dino, 16
Colle, Jean-Herve, 1492
Collins, Frank M., 1452
Collins, Gary D., 2215
Collins, John L., 1154

THE JOURNAL OF IMMUNOLOGY
Copyright © 1983 by The American Association of Immunologists
Vol. 131, No. 6, December 1983
Printed in U.S.A.

AUTHOR INDEX TO VOLUME 131

Abbas, Abul K., 1728
Abdel-Hafez, S. K., 1475
Abe, Ryo, 1646
Abo, Toru, 1822
Abrahams, I. Willard, 259
Abrams, Paul G., 1201
Ackerman, S. J., 2977
Adachi, Mitsunobu, 303, 1246
Adamowski, C., 2930
Adams, Dolph O., 1038, 2086
Adams, P. H., 2908
Adkinson, N. Franklin, Jr., 1936
Aglietta, Massimo, 2397
Ahmed, Parveen, 2458
Akiyama, Mitoshi, 175, 3085
Albini, B., 3021
Albino, Anthony P., 1595
Alexander, N. J., 2908
Allen, P. M., 2919
Altman, Amnon, 826
Alves, César Andrade, 972
Amento, Edward P., 743
Anderson, D. J., 2908
Anderson, Donna M., 1900
Anderson, Kenneth C., 244
Anderson, Sarah, 1616
Andreani, Marco, 2050
Andres, Giuseppe, 1802
Andrysiak, Patricia M., 1650
Antell, Laura, 1626
Appella, Ettore, 319
Arai, Sumio, 651
Araujo, Fausto G., 977
Archibald, Anna C., 207
Argilan, Fred, 132
Arnaout, M. Amin, 439
Arner, Leslie S., 2210
Arnold, Larry W., 2064
Aronson, R. A., 2796
Ascher, Nancy L., 617
Ashkar, Samy, 869
Askenase, P. W., 2675, 2687
Asofsky, Richard, 98
Atkins, Fred M., 1420
Atkinson, Kerry, 1771
Auerbach, Harvey S., 2420
August, J. Thomas, 1882
Ault, Kenneth A., 1178
Aune, Thomas M., 2301, 2848
Auriault, Claude, 464
Austen, K. F., 2958
Avrameas, Stratis, 2267
Ayala, Eleanor, 1
Azogui, Orly, 1205

Babcock, George F., 1789
Bach, Fritz H., 1318, 1622, 1670, 1676, 2135
Bach, Mark A., 365
Badger, Alison M., 1626
Bagot, M., 2735
Baird, S., 1576
Baird, S. M., 3073
Baker, Patricia J., 2484
Bakker, Roland H. J., 1234
Bakouche, Ouahid, 485
Balazs, I., 2821
Balch, Charles M., 1822
Ball, Edward J., 666
Balow, James E., 1797
Banda, Diane, 397
Barbarulli, Giordano, 1707
Barber, John, 1554
Barisas, B. G., 2924
Barlozzari, Teresa, 1024
Barnett, Eugene V., 217
Baron, Samuel, 1554
Barry, Wanda C., 70
Bartalini, Marcela, 1707
Bates, Michael, 244
Battye, F. L., 2983
Batuman, O. A., 533
Baum, L., 2930
Baxevanis, Constantin N., 628
Bazin, Herve, 1475
Bean, M. A., 3085
Bean, Michael A., 175
Beatty, Patrick G., 180, 2404, 2913
Beer, Dennis J., 1854
Behar, Samuel, 762
Behforouz, Nancy, 2576
Bell, M. K., 1698
Benacerraf, Baruj, 30, 2184
Bender, Paul E., 1626
Bender, T. P., 2882
Benike, Claudia J., 158
Benjamin, William R., 265
Benjamini, Eli, 561, 567, 2875
Benner, Robbert, 1629
Bennett, Michael, 2101, 2699
Bennink, Jack R., 471
Ben-Nun, A., 2810
Benson, Herbert, 1178
Bentley, Anna G., 1466
Berger, Melvin, 899
Bergman, Yehudit, 1876
Berke, Gideon, 50
Berliner, Judith A., 2368
Berman, Jeffrey S., 1854
Bernabeu, Carmelo, 2032
Bertoglio, Jacques H., 2279
Berzins, Klavs, 2000
Bevan, Michael J., 794
Bhogal, B. S., 2254
Biasi, Giovanni, 16
Bibro, Mary, 497
Bick, P. H., 2623
Biddison, William E., 152
Biggs, James C., 1771
Bikoff, Elizabeth, 103
Billings, Peter B., 347
Bindon, C., 2837
Binkley, Francis, 869
Biro, P. Andrew, 2032
Biron, Christine A., 991, 1539
Bishop, Gail A., 1849
Bishop, Nancy H., 1973
Bialock, J. Edwin, 1895
Bland, Catherine E., 915
Blattner, William A., 2021
Bloom, Marshall E., 1558
Bluestein, Harry G., 768
Blum, Arthur M., 2529
Blumenthal, Elliott, 794
Bocchieri, M. H., 533
Bona, Constantin A., 103
Bonagura, V., 2890
Bonavida, Benjamin, 1426
Bont, Willy S., 201
Booth, Roger J., 1289
Boraschi, Diana, 1707
Borel, Yves, 1762, 2204
Boros, Dov L., 959
Bortin, Mortimer M., 2050
Borysenko, Myrin, 1178
Bottero, Lisabianca, 1882
Boyer, Brigitte, 1339
Braley-Mullen, Helen, 2190
Brankovan, Vera, 175, 3085
Bratescu, Aurel, 1189
Braun, Marcus P., 180
Breathnach, S. M., 2741
Brentjens, Jan, 1802
Brestel, Eric P., 2515
Bretscher, Peter A., 1103
Brewster, Douglas R., 1613
Brewster, Marge A., 1011
Brickman, Chaim M., 1240
Britvan, L., 2705, 2710
Broder, Samuel, 725
Bron, C., 3091
Brooks, Colin G., 288, 1391, 2386
Brown, Alan R., 423
Brown, Eric J., 403, 409, 1443
Brown, Lawrence R., 165
Brown, Robert E., 1011
Brown, Thomas R., 1252
Broxmeyer, Hal E., 1300
Brunet, Gunter, 434
Brusdeilins, Martin, 2427
Bukowski, Jack F., 991, 1531
Bullock, W. E., 984
Burakoff, Steven J., 611, 1182, 1312, 2777
Burchell, Joy, 508
Burger, Reinhard, 1350
Burgess, A. W., 2983
Burowsky, Daphna, 1600
Burrichter, Heinz, 1591
Burton, Robert C., 1391
Bussolino, Federico, 1802, 2397
Buszello, Heinz, 548
Butler, Joseph L., 801
Butler, Larry D., 77, 1663
Butler-Browne, Gillian S., 2267

Cain, Charles A., 622
Caldwell, Peter R., 1802
Callard, Robin E., 1229
Calvert, Jane E., 1693
Cambier, J. C., 2641
Camussi, Giovanni, 1802, 2397
Capel, Peter J. A., 86
Capron, Andre, 464, 1475
Capron, Monique, 464, 1466, 1475
Carbone, Amy M., 1263
Carey, Gregory D., 1368
Carney, Desmond N., 497
Carpén, O., 2695
Carpenter, Charles B., 1065
Carpenter, Karen, 1754
Carrasco, Luis, 783
Carroll, Peter G., 1007
Carson, Dennis A., 719, 1776
Carter, Richard, 2557
Carter, W. H., 2623
Castles, James J., 2069
Censini, Stefano, 1707
Center, David M., 1854
Ceredig, Rhodri, 1085
Cerny, Jan, 2576
Cesari, Italo M., 464
Chan, C., 2868
Chang, Cecile C., 1318
Chang, Z., 2821
Charley, Michael R., 2101
Charon, J. A., 816
Charron, Dominique J., 1339
Chedid, Louis, 1492
Chen, Benjamin P. P., 57
Chen, Sally, 617
Chen, Y.-W., 3049
Chervenak, Robert, 1688
Chesnut, Robert W., 23, 109
Cheung, Kee, 207
Cheung, Roy K., 2291
Chia, David, 217
Chieco-Bianchi, Luigi, 16
Chiller, Jacques M., 23, 1663
Chin, Yee-Hon, 1368
Chiu, P., 3073
Chused, Thomas M., 1257, 2789
Ciampi, Antonio, 1115
Cibull, Michael L., 195
Cigen, Ragnhild, 1344
Claflin, J. L., 2882
Claman, H. N., 2682
Clark, David A., 540, 638
Clarke, Gregory, 1201
Clark-Lewis, Ian, 788
Clayberger, C., 2777
Clement, Loran T., 1214, 2757
Coe, John E., 1558
Coffman, Robert L., 64
Cohen, David J., 1065
Cohen, Irun R., 2316, 2810
Cohen, J. H. M., 2767
Cohen, J. John, 1688
Cohen, Leonard, 378
Cohn, Melvin, 1154
Coico, R. F., 2254
Cole, Barry C., 543, 1702, 2392
Coleman, Mary Sue, 195
Collavo, Dino, 16
Colle, Jean-Herve, 1492
Collins, Frank M., 1452
Collins, Gary D., 2215
Collins, John L., 1154

Colombatti, M., 3091
Colot, M., 816
Colten, Harvey R., 439, 2416, 2420
Colvin, Robert B., 743
Cone, R. E., 2859
Conlon, John C., 503
Conlon, Paul J., 1260
Cook, S. L., 2796
Cooper, David A., 186, 1167
Cooper, Herbert L., 341
Cooper, Max D., 1306, 1693, 1822
Copelan, Edward A., 2017
Copeland, Terry D., 282
Cordier, G., 2767
Correa-Oliveira, Rodrigo, 1460
Coutinho, Antonio A., 2158
Craddock, Garnet R., 1582
Craig, Susan W., 370
Crapper, Richard M., 923
Crary, Bruce, 1178
Cremer, M. A., 2995
Crimmins, M., 2777
Croy, B. Anne, 540
Cruikshank, William W., 1854
Cuciu-Foca, N., 2890
Cuttitta, Frank, 497
Czerniecki, M., 2837

Dagg, Martha K., 1214
Daha, Mohamed R., 1924
Dales, Samuel, 1332, 1546
Daley, John F., 244
Damle, Nitin K., 2296
Danek, Adrian, 1173
Danel, L., 2767
Darby, Beree, 2432, 3052
Datta, Syamal K., 2232
David, John R., 1616
Davie, Joseph M., 1326, 2458
Davignon, Jean-Luc, 1073
Davis, Charles E., 450
Day, Eugene D., 275
Daynes, Raymond A., 543, 1702
De Baets, Marc, 2452
Debatin, Klaus-Michael, 833
Debre, Patrice, 1339
Decker, Jean M., 725
de Cordoba, Santiago R., 1565
DeFreitas, Elzine C., 23
Deguchi, H., 2751
Deibel, Martin R., Jr., 195
Deimann, Winfried, 833
DeLeo, Albert B., 2601
del Guercio, Paolo, 1283
Delovitch, Terry L., 2246
DeLuca, Dominick, 1582
Demant, Peter, 1080
Demars, Robert, 1318
Denis, Kathleen A., 2273
Depper, Joel M., 690
Descamps-Latscha, Beatrice, 2500
de Souza, Wanderley, 972
de Vries, Jan, 2032
deVries, Jan E., 201, 678
DeWolf, William C., 1007
D'Hoostelaere, L. A., 1570
Dialynas, Deno P., 2178, 2445
Diamond, Betty, 674
Dianzani, Ferdinando, 1554
Dichter, Marc A., 2533
Dick, Robert F., 1609
Diehl, Volker, 1591
Diffley, Peter, 1983
Dighiero, Guillaume, 2267
Dinarello, Charles A., 801
Dintzis, Howard M., 2196
Dintzis, Renee Z., 2196
Distaso, Judy A., 1209
Djeu, Julie Y., 2379
Dobos, Claraine B., 1138
Doekes, Gert, 1924
Doherty, Peter C., 471
Donowitz, Gerald R., 1784, 1994
Dopfer, Roland, 2332
Dore, Jean Francois, 485
Dorshkind, Kenneth, 2240
Dotterer, Waldemar, 520
Dougherty, Suanne F., 2379
Doughty, Barbara L., 1466
Douglas, Herndon, 450
Dröge, Wulf, 520, 548
Drysdale, Beth-Ellen, 2362
Dukovich, Mitchell, 1834
Duquesnoy, Rene J., 1318
Durant, Debra A., 697
Durbin, Helga, 508
Dvorak, A. M., 2965
Dvorak, H. F., 2965
Dwyer, D. M., 454
Dwyer, Dennis M., 1496
Dy, Michel, 282

Eardley, Diane D., 2154, 2576
Eastcott, Jean W., 2232
Eda, Yasuyuki, 1294
Edgington, Thomas S., 749
Edwards, Anne, 171
Edwards, Peter A., 2368
Eerola, Erkki, 120
Egan, Robert W., 429
Eggertsen, Gösta, 1920
Ehrlich, Paul H., 1900, 1906
Eisen, Herman N., 2477
Eisenbarth, George S., 773, 1195
Eldridge, John H., 1131, 2616
Ellis, Thomas M., 2323
Ellner, Jerrold J., 954
Elmajian, D. A., 3073
Ely, John M., 1274
Endres, Robert O., 794, 1656
Engers, H. D., 1522, 2165
Engers, Howard, 251
Engleman, Edgar G., 158, 2296
Epstein, Lois B., 768
Epstein, Suzanne L., 359
Erb, P., 2714
Erickson, Bruce W., 2258
Erlich, Henry A., 977
Ernisse, B. J., 3042
Eskola, Jussi, 1218
Esparza, Inmaculada, 2117
Evans, Robert L., 536
Ewert, Donald L., 3036

Fairwell, Thomas, 319
Falk, Werner, 520
Falkoff, Reuben J. M., 801
Fan, John, 1426
Fanning, Virginia, 223
Fargion, Silvia, 497
Farrar, John, 633
Farrar, John J., 1838
Fast, Loren D., 1742, 2404
Fauci, Anthony S., 801, 2977
Favata, Margaret F., 1808
Fearon, Douglas T., 684
Fedorko, Joseph, 497
Feit, Carl, 1300
Feller, A. C., 2719
Fellous, Marc, 2551
Feng, H. M., 2165
Feng, Hui-Min, 251
Ferreira, Arturo, 1565
Ferrero, Dario, 736, 1882
Feuillet-Fieux, Marie-Noëlle, 2500
Fiedel, Barry A., 1416
Fields, Bernard N., 2533, 2539
Figdor, Carl G., 201
Finberg, Robert, 30, 2539
Finbloom, D. s., 2784
Finerty, J. F., 454
Finke, James H., 1487
Finkelman, Fred D., 593, 601, 2107, 2226
Finlay, Deborah, 2032
Finley, R., 1522
Fiorilli, Massimo, 2046
Fischer, Dina G., 445
Fitch, Frank, 282
Fitch, Frank W., 1056, 1274, 2178, 2445, 2651, 2656
Fitzgerald, Kathleen A., 186
Fitzmaurice, Leona C., 1000
Fogelman, Alan M., 2368
Fok, Kam-Fook, 2258
Fong, Sherman, 719, 762
Foon, Kenneth A., 1201
Ford-Hutchinson, Anthony W., 434
Forget, Adrien, 1966
Fox, Robert I., 749, 762
Fradelizi, Didier, 1205
Francis, Mary K., 736
Francus, Tova, 882
Frangione, Blas, 1322, 2490
Frank, Michael M., 403, 409, 899, 1240, 1443, 2563, 2570
Franklin, E. C., 1322
Freed, John H., 352
Freitas, Antonio A., 2158
Frenkel, A., 2810
Fresno, Manuel, 783
Fridman, W. H., 303
Friedman, Aharon, 2316
Friedman, Alan W., 712
Friedman, Haya, 329
Friedman, Marc M., 915
Friedrich, Wilhelm, 2332
Frieri, Marianne, 1942
Fries, Louis F., 1240
Frisman, D. M., 3073
Fuge-Abruzzini, L. N. K., 845
Fuge-Abruzzini, Linda N. K., 1344
Fujii, Masahiro, 1611
Fujinami, Robert S., 1332, 1546
Fukuyama, Kimie, 397
Fuller, Steven A., 195
Fuller-Farrar, Janet, 633, 1838
Fulton, Amy M., 2079
Fulton, R. Jerrold, 1326
Furthmayr, Heinz, 864

Gaither, Thelma A., 409, 899
Galli, S. J., 2965
Gallo, Robert C., 2021
Gardiner, P. R., 454
Gartland, G. L., 2757
Garver, Fred A., 1871
Gateley, C. L., 2853
Gathings, William E., 1693
Gazdar, Adi F., 497
Gefter, M. L., 2614
Gelfand, Erwin W., 2291
Gemsa, Diethard, 833
George, Jack M., 1173
Gerlier, Denis, 485
Germain, Ronald N., 2025
Gershon, M. D., 2687
Gershon, Richard K., 2154, 2859
Gershwin, M. Eric, 2069, 2219
Gewurz, Henry, 1416, 2930
Ghezzi, Pietro, 1707
Gigli, Irma, 1400
Gilbertson, Timothy A., 719
Gillespie, E., 2945
Gilliam, James N., 2101
Gillin, Frances D., 2004
Gillis, Steven, 288, 2386
Gioud, Martine, 269
Girard, Yves, 429
Glasebrook, A. L., 2165
Gleich, G. J., 2977
Glimcher, L. H., 2868
Glock, R. D., 997
Glorioso, Joseph C., 1849
Gluckman, Eliane, 1205
Goetzl, Edward J., 551, 906, 1613
Goidl, Edmond A., 1978
Gold, Warren M., 906
Goldberger, Gabriel, 2416
Golde, David W., 2368
Goldings, E. A., 2630
Goldman, Michel, 251
Goldman, Robert C., 2563, 2570
Goldstein, Allan L., 148
Goldstein, Gideon, 152, 1754
Goldstein, Ira M., 397
Goldwasser, Eugene, 282
Golub, Robert M., 2500
Gonatas, N. K., 2805
Goñi, Fernando, 1322
Good, M. F., 2662
Good, Robert A., 2219
Goodall, G. J., 821
Gooding, Linda R., 2580
Gorczynski, Reginald D., 2246
Gorczynski, Reginald M., 1115
Graham, J. A., 3032
Graham, Sam D., Jr., 794
Grammer, Leslie C., 1949
Granfors, Kaisa, 120
Grant, C. K., 3042
Graziano, F. M., 2675
Green, Bridget, 1619
Green, J. A., 2827
Green, Ralph, 2117
Green, W. R., 3078
Greene, Mark I., 1728, 2533, 2539
Greene, Warner C., 690
Greenstein, J. L., 2777

Gregerson, Dale S., 259
Greig, Russell G., 1626
Gresham, H. D., 892
Grey, Howard M., 23, 109
Griffin, J. D., 232
Griffith, Rogers C., 2458
Grinstein, Sergio, 2291
Griswold, Donald E., 1626
Groopman, Jerome E., 2368
Gros, O., 3091
Gros, Philippe, 1966
Grotendorst, Cynthia A., 2557
Guelde, Gretchen, 2468
Guimezanes, Annick, 1073
Gullberg, Martin, 19
Gunderson, L., 2675
Gurish, Michael F., 1702
Guthman, D. A., 929
Gutmann, D. H., 2919

Haaijman, Joost J., 1629
Haberland, Margaret E., 2368
Habu, Sonoku, 1531
Haimovich, Joseph, 1600
Hall, Nicholas R., 148
Hallgren, Helen M., 191
Halpern, M. S., 3036
Hamada, Shigeyuki, 1131
Hamano, Teruaki, 98
Hamel, Rene, 434
Hamilton, M. S., 2908
Hammer, C. H., 892
Hammer, Carl H., 403, 409, 899, 2563, 2570
Hanaoka, Masao, 2307
Hanff, Philip A., 1973
Hank, Jacquelyn A., 165
Hansburg, Daniel, 319
Hänsch, G., 892
Hansen, John A., 175, 180, 2296, 2404, 2913
Hansen, Ted H., 359, 2440
Hansmann, M-L., 2719
Hapke, Constanze, 2427
Harada, Hirotomo, 238
Haran, Gregory, 171
Harcus, Jane L., 1994
Hard, R. C., Jr., 2623
Harden, Elizabeth A., 773, 1195
Hargrove, Myrthel E., 1734
Harley, J. B., 2977
Harris, Alan W., 788
Hart, Gerald W., 352
Harvey, V. S., 2965
Hashim, George A., 275
Hasic, Enisa, 171
Hasler, Friedrich, 768
Hattori, T., 662
Haughton, Geoffrey, 2064
Hauptman, S. P., 533
Hauser, Stephen L., 1178
Hauser, William E., Jr., 458
Hayashi, H., 2989
Hayes, Colleen E., 1380
Hayes, Edward C., 429
Haynes, Barton F., 773, 1195
Healy, C. T., 2843
Hecht, Toby T., 1049
Heinz, Fritz, 2332
Helderman, J. Harold, 644
Helin, Heikki J., 749
Hellman, Ulf, 1920
Hemler, Martin E., 334, 1195
Hempstead, J. L., 821
Henderson, Louis E., 282, 810
Hengartner, H., 475
Henin, Y., 2735
Henney, Christopher S., 288, 1391, 2386
Hensley, Lucinda L., 773
Henson, Peter, 794
Heppner, Gloria H., 2074, 2079
Herberman, Ronald B., 503, 662, 1024
Hernandez, A. D., 2995
Hersey, P., 2837
Hersey, Peter, 171
Hewetson, John F., 810
Hickey, W. F., 2805
Hieny, Sara, 1460, 1481
Hill, Jeffrey, 794
Hinrichs, David J., 4
Hinuma, Yorio, 1611
Hirata, F., 662
Hiserodt, J. C., 2705, 2710
Hizuta, A., 662
Hoar, David I., 1619
Hoban, Caroline, 1178
Hoch, Sallie O., 347
Hochmann, Agnes, 251
Hodgdon, James C., 186, 1167
Hoffman, Rosemary A., 617
Hoffman, T., 662, 2821
Hogan, R. Nick, 491
Hogarth, P. Mark, 546, 1363
Holme, George, 434
Holmes, Kevin L., 1714
Holoshitz, J., 2810
Honda, M., 2989
Hong, Jin-Xin, 801
Hooijkaas, Herbert, 1629
Hopkins, Ralph F., III, 810
Howard, Maureen, 633, 1838
Howard, Russell J., 2557
Howe, Rawleigh C., 2141
Hu, P. C., 3032
Hu, Shu-Kuang, 2154
Huang, C-H., 3032
Huang, Y-S., 3032
Huberts, Hans H., 2427
Hudson, Jerry L., 1000
Hueniken, Myra, 762
Huff, Thomas F., 1090
Hughes, Thomas K., 1895
Hugli, Tony E., 2258
Hullett, Debra A., 1380
Humphres, Robert C., 4
Humphrey, W., Jr., 1570
Hundley, T. R., 2784
Hurme, M., 658
Hurrell, Susan M., 1017
Hurwitz, Ester, 1600
Hurwitz, Julia L., 471
Husmann, Matthias, 1350
Hussain, Rabia, 706, 1460, 1516
Hussey, Rebecca E., 186, 1167

Igarashi, Ikuo, 1527
Ihle, James N., 282
Iizasa, Taizo, 1776
Ijssel, Hans, 678
Ikeda, Hisami, 1595
Ikeda, Michael T., 1860
Ikeda, Richard M., 2069
Ikezawa, Zenro, 1646
Infante, A. J., 2726
Inoue, Tomio, 2508
Isakson, P., 3049
Isersky, Chaviva, 388
Ishikawa, Hiromichi, 1142
Ishikawa, Sho, 2059
Ishizaka, A., 2751
Ishizaka, Kimishige, 1090, 1954
Ito, Shigenori, 1865
Itoh, Kyogo, 651
Ivanyi, Dagmay, 1080
Iwata, Makoto, 1090, 1954
Izzi, Joyce M., 1416

Jaaijman, Joost J., 1629
Jackola, Duaine R., 191
Jacobsen, Frederick, 1000
Jacoby, David R., 1765
Jaffe, Charles L., 1987
Jaffee, B. D., 2682
Jalkanen, Sirpa, 120
James, K., 2930
James, S. L., 948
James, Stephanie L., 1481
Jarrett, O., 3042
Jenkins, Robert N., 2147
Joens, L. A., 997
Johnson, William J., 1038
Joiner, Keith A., 409, 1443, 2563, 2570
Jones, F. R., 3042
Jones, Michele, 2601
Jones, Patricia P., 315
Jones, S., 3049
Jordan, Craig, 1554
Jordan, Yvonne, 298
Joseph, Michel, 1475
Joslin, Fenneke G., 269
Juliano, Lisa, 1300
Julius, Michael H., 581
Jung, Chan Y., 1126
Jyonouchi, Harumi, 2219

Kagey-Sobotka, Anne, 1936
Kagnoff, Martin F., 2210
Kahan, Barry D., 712
Kakiuchi, Terutaka, 109
Kalil, Jorge, 2551, 2735
Kaliner, M., 929
Kan, Edmond A. R., 536
Kanagawa, Osami, 606
Kaneoka, Hidetoshi, 158
Kang, A. H., 2995
Kannagi, Mari, 1611
Kannapell, Carol C., 2458
Kaplan, H. J., 2746
Kapp, J. A., 2843
Kappler, John, 2178, 2814
Kappler, John W., 794, 1656
Karch, Helge, 6
Karp, David R., 1405
Kasahara, Tadashi, 2379
Kasakura, Shinpei, 2307
Kasper, Kenneth C., 491
Katayama, Satoru, 217
Katz, Arieh, 329
Katz, David H., 826
Katz, S. I., 2741
Kau, Cheng-Lin, 2262
Kauffman, Robert S., 2539
Kaufman, Katie, 2246
Kaufmann, Yael, 50
Kaushal, Deep C., 2557
Kawai, Tadahsi, 238
Kawase, Ichiro, 288
Kay, H. David, 1784
Kay, Robert M., 2416
Kazim, L., 2726
Kearney, J. F., 1375
Kearney, John F., 2411
Kees, Ursula, 833
Keller, Jonathan, 282
Kennedy, Marion, 1115
Kenny, James J., 2468
Kholy, Aziz El, 954
Kiefer, Charles R., 1871
Kierszenbaum, Felipe, 1504, 3028
Kikutani, Hitoshi, 1961
Kilpatrick, J. Michael, 2411
Kim, Byung S., 13
Kim, Mary F., 1693
Kim, Yoon B., 1438
Kimura, H., 2805
Kincade, Paul W., 572, 2219
King, Donna P., 315
King, Donald W., 2890
Kingsbury, David T., 491
Kishi, Hiroyuki, 1961
Kishimoto, S., 2751
Kishimoto, Tadamitsu, 1961, 2751
Kiyono, H., 2616
Kiyotaki, Masaya, 1214
Klapper, David, 2064
Klapper, David G., 706
Klein, Jan, 325, 628, 1646
Klein, John R., 794
Klyczek, Karen K., 1380
Kniep, Bernhard, 1591
Knost, James A., 1201
Knowles, Robert W., 851
Knudsen, Peter, 725
Knutson, David W., 217
Koene, Robert A. P., 86
Kohl, Steve, 1455
Kohler, Heinz, 365
Kolb, William P., 416
Koren, Hillel S., 445
Kortmann, Christine, 2332
Koshland, Marian E., i
Koski, Carol L., 1411
Kostar, Frederick T., 115
Kotani, Hiroyuki, 753
Kotzin, Brian L., 269
Kraeuter-Kops, S., 2687
Krakauer, Teresa, 2440
Kramer, Wiebke, 833
Krammer, Peter H., 833, 3049
Krane, Stephen M., 743
Krangel, Michael S., 1312, 2935
Kreeftenberg, Johan G., 1234
Krensky, Alan M., 611, 2777
Krensky, Allan M., 1182
Kruisbeek, Ada M., 1650
Ku, Cecilia S. L., 1416
Ku, George S. B., 2494
Kubelka, Claire, 833
Kubota, Eiro, 1142
Kubota, Masaru, 1776

Kulczycki, Anthony, Jr., 378
Kumagai, Katsuo, 651
Kumar, V., 2699
Kung, P., 2890
Kuribayashi, Kagemasa, 288
Kuritani, Taro, 1306
Kurlander, Roger J., 140
Kurnick, James T., 743
Kurosaka, Masahiro, 2282
Kutz, Ilan, 1178

Lala, Peeyush K., 2348
Lalande, Marc E., 2420
Lambert, P. H., 1522
Lambert, Paul Henri, 251
Landay, A., 2757
Landreth, Kenneth S., 572
Lanier, Lewis L., 1789
LaRosa, Francisco, 794
Larson, L., 2675
Larsson, Eva-Lotta, 19
Laskin, Carl A., 1121
Last-Barney, Kathleen, 806
Latt, Samuel, 2420
Lauffenburger, D., 940
Lauzon, G. J., 3064
Layton, J., 3049
Lazarus, Herbert, 2038
Lazarus, Kenneth J., 275
Lazdins, J. K., 1481
Le, An My, 1789
Le, J., 2821
Leavitt, Richard, 503
Lebel, Bernard, 282
Ledbetter, Jeffrey A., 180, 2913
Ledford, Dennis K., 1322
Lee, Grace, 572
Lee, M. C., 1375
Leemans, Jack M., 201
LeFever, Ann V., 2050
LeGrue, Stephen J., 712
Lehmeyer, Joyce E., 1214
Lehto, V-P., 2695
Leibowitz, Julian L., 2595
Leibson, H. James, 794
Leiserson, William M., 98
Leive, Loretta, 2563, 2570
Lemanske, R. F., Jr., 929
Lems, Simon P. M., 86
Leonard, Warren J., 690
Lepault, Francoise, 64
Lerch, Peter G., 851
Lesavre, P., 1396
Lesley, J., 1576
Leung, Kam H., 445
Levitt, Daniel, 365
Lévy, Daniel, 2551
Levy, J-P., 2735
Levy, Julia G., 1843
Levy, Ronald, 1876
Levy, Shoshana, 1876
Lewis, Mark, 2017
Lewis, R. A., 2958
Lichtenstein, Lawrence M., 1936, 2965
Lieberman, Michael M., 1
Lieberman, R., 1570
Lieberman, Rose, 1121
Lin, Ying, 1154
Linette, Gerald, 1466
Lipsky, Peter E., 2282
Lissner, C. R., 3006
Little, Cameron, 497
Liu, W. T., 778
Livingston, Philip O., 2601
Lloyd, Kenneth O., 1595
LoCascio, Nicola J., 2064
Loegering, D. A., 2977
Loggen, Henk G., 1234
Loken, Michael R., 1056, 2445
Lombardo, Donna L., 429
Longenecker, B. M., 3064
Longo, Dan L., 1049
Longton, Gary, 180
López, A. F., 2983
Lorber, Marc I., 1056
Louis, J. A., 1522, 2165
Louis, Jacques, 251
Loveless, Scott E., 2074
Loveren, H. V., 2687
Lovett, D. H., 2830
Lovett, Michael A., 1973
Lu, Li, 1300
Luger, T. A., 816
Lundgren, Katarina, 2000
Lundwall, Åke, 1920
Lunney, J. K., 2939
Lutz, Paula M., 2064
Lynberi, Peggy, 2267
Lynch, David H., 1702

MacDonald, H. Robson, 1085
MacGlashan, Donald W., Jr., 1936, 2965
Mackel, Anne M., 1582
MacRae, Susannah, 1115
Mage, Rose G., 1000
Magilavy, D. B., 2784
Magrath, Ian T., 899, 1797
Mahoney, Keith H., 2079
Maier, T., 1843
Majda, J., 1576
Malavasi, Fabio, 2397
Maluish, Annette C., 503
Mampaso, Francisco, 1268
Mandell, Gerald L., 1784
Mann, D., 2699
Mann, Dean L., 725, 2021
Männel, Daniela, 520
Marchalonis, John J., 1582
Marcus, Donald M., 864
Marino, Phillip A., 1038
Marmer, Daniel J., 1011
Maron, Ruth, 2316
Marone, G., 2945
Marquardt, Diana L., 934
Marrack, Philippa, 794, 1656, 2178, 2814
Marrari, Marilyn, 1318
Marsh, David G., 706
Marti, Gerald, 244
Martin, Paul J., 175, 180, 2913
Massey, Patrick B., 13
Mastin, J. P., 2086
Masuda, Tohru, 303, 1246
Masuho, Yasuhiko, 1762
Matera, Lina, 736
Mathes, Laurence, 2017
Matheson, David S., 1619
Matis, Louis A., 1049
Matsumoto, Hideo, 1865
Matsumoto, S. S., 2762
Matsuyama, Masako, 1611
Mauer, Ursula, 1350
May, Richard D., 1108
Maycock, Alan L., 429
Mayer, Eugene P., 1189
Mayer, Manfred M., 1411
Mayumi, Makoto, 238
Maziarz, Richard T., 2032
Mazié, Jean-Claude, 2267
McCarley, Dean L., 1780
McCarthy, Susan A., 1670, 1676
McCarthy, W. H., 2837
McCartney-Francis, Nancy, 1000
McClain, Edward J., 2515
McClatchey, Scott, 1056
McCutchan, Thomas F., 962
McFadden, Marcia L., 1917
McGhee, Jerry R., 1131, 2616
McGillis, Joseph P., 148
McGuire, Byron S., Jr., 1871
McKean, D. J., 2726
McKean, David J., 2025
McKenzie, Ian F. C., 546, 1363
McKimm-Breschkin, Jennifer L., 788
McMahon-Pratt, Diane, 1616, 1987
Meade, R., 2687
Medicus, Rudolph G., 439
Medlock, Eugene S., 572
Megson, Mary, 725
Melamed, Julian, 439
Melino, Michael R., 359
Mellon, M. H., 2772, 3001
Meltzer, M. S., 948
Mencia-Huerta, J-M., 2958
Mendonça-Previato, Lúcia, 972
Merluzzi, Vincent J., 806
Mertelsmann, Roland, 806, 2356
Mescher, Matthew, 2025
Metcalf, D., 2983
Metcalf, Eleanor S., 593, 601
Metcalfe, Dean D., 915, 1420, 1942
Meuer, Stefan C., 186, 1167
Meyers, Christine, 911
Michalek, Suzanne M., 1131, 2616
Micksche, M., 816
Middleton, Marjorie H., 2196
Mikhael, Anwar, 2101
Miki, Yoshitsugu, 1961
Milford, Edgar L., 1065
Miller, Charles A., 1822
Miller, Geraldine P. G., 1455
Miller, James N., 1973
Miller, Louis H., 2557
Miller, R. A., 2864
Miller, Richard G., 45, 2128
Miller, Sandra C., 92
Miller, Stephen D., 77, 1688
Miller, T. B., 984
Minai, Masaru, 2524
Minna, John D., 497
Mischler, S., 2714
Misiti, John, 2046
Mitchell, David M., 1229
Mittler, Robert S., 1754
Miyama-Inaba, Muneo, 303
Miyawaki, Toshio, 731
Miyazaki, Tokiko, 1865
Mizel, Steven B., 1834
Modabber, Farrokh, 1492
Mohagheghpour, Nahid, 2296
Mohanakumar, T., 2323
Moloshok, Thomas, 2490
Mond, James J., 593, 601, 633, 2107, 2226
Monner, David A., 1591
Monos, Dimitri S., 341
Monroe, J. G., 2641
Montgomery, Barbara, 2348
Mookerjee, Basab K., 1126
Moore, Malcolm A. S., 2356
Moore, Robert N., 2374
Morgan, Edward L., 2258
Morgan, J. I., 821
Morimoto, Chikao, 1167, 1209, 1762
Morisaki, Ichijiro, 1131
Morrow, Phillip R., 561, 567, 2875
Moscicki, Richard A., 743
Moser, Gina, 1728
Mosteller, L. M., 2616
Moustafa, Zeinab A., 1906
Moyle, William R., 1900, 1906
Muchmore, Andrew V., 725
Mühlradt, Peter F., 1591
Müler, Wolfgang, 2332
Mullenax, Jean, 977
Müller, Christa E., 877
Muller, Claude P., 1356
Müller-Eberhard, Hans J., 1930
Mulshine, James L., 497
Muñoz, Alberto, 783
Munoz, John J., 1954
Murachi, Takashi, 2307
Muraguchi, Atsushi, 801
Murakawa, Yohko, 753
Muraoka, Shizuko, 45
Murray, Christine, 2021
Murray, Henry W., 384, 2542
Murray, J. H., 2859
Muul, Linda M., 2226
Myrdal, Sigrid E., 869
Myrvik, Quentin, 2104

Nabholz, M., 3091
Nachtsheim, D. A., 3073
Nadler, L. M., 232
Nadler, Lee M., 244
Nagarkatti, Prakash S., 638
Nagelkerken, Lex M., 2328
Nagy, Janice, 611
Nagy, Zoltan A., 325, 628, 1646
Nahm, Moon H., 1326, 2458
Nakoinz, Ilona, 1028
Narimatsu, Hisashi, 37
Nash, Theodore, 2520
Nash, Theodore E., 2004
Nasrallah, Victor N., Jr., 2104
Nathan, Carl F., 384
Natovitz, Patricia, 1481
Neiders, M., 3021
Nell, Laura J., 701
Nelson, David L., 1222
Nepom, Jerry T., 2533, 2539
Neubauer, Russell H., 810
Neuland, Carolyn, 2021
Neussen, M. E., 997
Newman, Walter, 180, 288, 1149, 1742, 2404
Nguyen, Anh T., 2500
Nichols, Elizabeth A., 2440
Nicola, N. A., 2083
Niederhuber, J. E., 2919
Niederkorn, Jerry Y., 2587, 2670

Nilson, A., 2726
Nisengard, R. J., 3021
Nishinarita, S., 1570
Nixdorff, Kathryn, 6
Nixon, Daniel W., 869
Nonaka, Makoto, 1646
Nordin, Albert A., 2215
Noreen, Harriet, 1318
Norlund, J. J., 2687
Northoff, Hinnak, 1433
Noseworthy, John H., 2533, 2539
Nossal, G. J. V., 554, 2662
Novikovs, Legita, 899
Nunez, Gabriel, 666
Nurmi, Tapio, 1218
Nussenzweig, Victor, 1565

O'Brien, A. D., 2613, 3006, 3014
Ochiai, Yukiko, 864
O'Connell, Kathryn A., 2580
O'Dorisio, M. Sue, 1173
O'Dorisio, Thomas M., 1173
Oettgen, Herbert F., 2601
Ohara, Junichi, 1294
Ohsugi, Yoshiyuki, 2069
Ohta, Nobuo, 2524
Ohta, Toshiyuki, 1865
Ohtani, Osamu, 397
Ohzeki, Shigeharu, 731
Okumura, Ko, 1531
Olabuenaga, Susana, 288
Olabuenaga, Susana E., 2386
Olanow, C. Warren, 773
Old, Lloyd J., 1595, 2601
Oldham, Robert K., 503, 1201
Olds, G. Richard, 954
Oldstone, M. B. A., 475
Oldstone, Michael B., 1332, 1546, 1765
O'Leary, James J., 191
Olsen, Richard, 2017
Olson, Merle S., 416
Olsson, I., 2977
Omata, Yoshitaka, 1527
Ong, Richard, 397
Oppenheim, J. J., 816
Oppenheim, Joost J., 265, 1160, 2379, 2853
Opstelten, D., 2635
Orme, Ian M., 1452
Orosz, Charles G., 2135
Oroszlan, Stephen, 282, 1808
Ortaldo, John R., 503
Osathanondh, R., 232
Osborne, Barbara A., 1386, 2939
Osmond, D. G., 2635
Osserman, Elliott F., 1871
Osterhaus, Albert D. M. E., 1234
Ottesen, Eric A., 1516
Out, Theo A., 2328
Ovadia, Haim, 1263
Ozaki, Y., 2751

Pace, Judith L., 826
Palaszynski, Edmund, 282
Palker, Thomas J., 1195
Pandolfi, Franco, 2046
Pangburn, Michael K., 1930
Panknin, Sabine, 520
Parham, Peter, 856, 2895
Park, Edward, 244
Parker, Charles J., 2484
Parwaresch, M. R., 2719
Pasqualetto, Elena, 1707
Pasternack, Mark S., 2477
Patek, Paul Q., 1154
Paterson, Philip Y., 275, 1263
Patterson, Roy, 1949
Paul, William E., 633, 1838
Pavirani, Andrea, 1000
Pawlowski, Irene, 1802
Payan, Donald G., 551, 1613
Peacock, J. S., 2924
Pearlstein, Edward, 1400
Pearson, Richard D., 1994
Peck, Ammon B., 2432
Pembrey, Richard G., 1771
Pennell, Christopher A., 2064
Pennington, L., 2939
Perek, Yafa, 1600
Perez, H. Daniel, 397
Perez-Rojas, Gloria, 158
Peri, B. A., 2651, 2656
Perlmann, Hedvig, 2000
Perlmann, Peter, 2000, 2340
Perry, Linda L., 2533
Perussia, Bice, 223
Pesando, John M., 2038
Pessano, Silvana, 1882
Peter, Hans H., 2332
Peters, K-P., 2719
Peters, Stephen P., 1936, 2965
Phillips, Joseph H., 1789
Phillips, Martin J., 906
Phillips, Robert A., 2240
Phillips, S. Michael, 1466, 1475
Phipps, Richard P., 2122
Piacibello, Wanda, 2397
Piatier-Tonneau, Dominique, 1339
Pichler, Werner J., 2332
Pidgeon, Charles, 311
Piechuta, Hanna, 434
Pierce, Carl W., 2301, 2848
Pierce, Nathaniel F., 115
Pierres, Anne, 2445
Pierres, Michel, 2445
Pike, Beverley L., 554
Pillai, P. S., 587
Pious, Donald, 1312, 2935
Piper, Margaret, 587
Pizer, Ellen, 2533
Pizzolato, Marco, 1322
Plata, Fernando, 2551
Platzer, Erich, 1300, 2356
Plaut, M., 2945
Plummer, J. M., 3001
Poirier, Marie-France, 1283
Pollack, Sylvia B., 1391
Popovic, Mikulas, 2021
Poste, George, 1626
Potter, Jeffrey W., 697
Potter, M., 1570
Pottmeyer, Christiane, 548
Praz, F., 1396
Preesman, Aria A., 1629
Prensky, W., 2821
Prestidge, Ross L., 1289
Previato, José Osvaldo, 972
Price, T. H., 2913
Primi, Daniele, 1816
Prusiner, Stanley B., 491
Pruzansky, Jacob J., 1949
Prystowsky, Michael B., 282
Ptak, W., 2687, 2859
Pure, E., 3049
Pyne, K., 2965

Quan, Zoe S., 2445
Quigley, James P., 2494
Quintáns, José, 1609, 2445

Rabin, Harve, 810
Race, Richard E., 1558
Radzun, H. J., 2719
Rajewsky, Klaus, 877
Ralph, Peter, 1028
Ramila, G., 2714
Ramm, Louise E., 1411
Ramsey, Joseph, 403
Rao, Patricia E., 152, 1754
Raschke, W., 1576
Raska, Karel, III, 325
Ratcliffe, Michael J. H., 581
Ray, Marilyn C., 1096
Razin, E., 2958
Rearden, A., 3073
Reddy, E. Premkumar, 1000
Redington, T. J., 984
Reed, E., 2890
Reed, Steven G., 1978
Reimann, Joerg, 2128
Reiner, Neil E., 1487
Reinherz, Ellis L., 186, 1167, 1209
Reitnauer, Pamela J., 165
Remington, Jack S., 458, 977
Rener, Joan, 2557
Rennick, Donna M., 561, 567, 2875
Resch, Klaus, 1433
Reske, Konrad, 1350
Revillard, J.-P., 2767
Reynolds, Craig W., 132, 1024
Rich, Robert R., 2147
Rieger, Christian H. L., 2332
Riley, Lela K., 195
Rimm, I. J., 232
Rinehart, John J., 2017
Rinnooy Kan, E. A., 536
Rinnooy Kan, Edmond A., 2356
Rivera, Juan, 388
Robb, Richard J., 690
Robbins, Elizabeth, 611
Roberts, Denise, 1994
Roberts, Lee K., 514
Roberts, Mary, 1949
Roberts, Walden K., 794
Robinson, Michael F., 207
Robinson, Randy R., 2025
Rocha, Benedita, 2151
Roche, J. K., 2796
Rodrigues, Maurício Martins, 972
Roebber, Marianne, 706
Rogers, Joy, 2452
Rokach, Joshua, 429
Ron, Y., 2687
Roopenian, Derry C., 2135
Rose, Lynn M., 1742
Rosenstein, R. W., 2859
Rosenstreich, D. L., 2613
Rosenthal, Alan S., 429
Rosenthal, K. L., 475
Rosenthal, P., 232
Roses, Allen D., 773
Rossant, Janet, 540
Rosse, Wendell F., 2484
Roters, Silene B., 1978
Rothberg, R. M., 2651, 2656
Rothermel, Constance D., 2542
Rothlein, Robert, 1438
Rothman, C., 940
Rothstein, Jay, 1834
Rotter, Varda, 329
Rouse, Barry T., 479, 2374
Roux, Kenneth H., 2411
Rouyre, Sylvie, 2267
Rovera, Giovanni, 1882
Royston, Ivor, 762
Rubin, Berish Y., 1300, 2542
Rubin, Robert L., 269
Rubinstein, Pablo, 1565
Ruddle, Nancy H., 70
Rudikoff, Stuart, 1386, 2939
Ruebner, Boris, 2069
Ruedi, J., 3001
Russell, John H., 1138, 2141
Russell, Stephen W., 826
Rutherford, W. John, 298
Ruuskanen, Olli, 1218
Ryan, J. L., 2830

Sachs, David H., 359, 2939
Sacks, David, 966
Sacks, David L., 962, 1511
Sadamoto, Kenichiro, 175, 3085
Sadlik, J. R., 2821
Saez, S., 2767
Sagone, Arthur, 2017
Saito, Atsushi, 1527
Saito, Kazuhisa, 37, 1142
Sakane, Tsuyoshi, 753
Saksela, E., 2695
Sakurai, Haruhisa, 1527
Salmona, Mario, 1707
Salomon, Daniel R., 1065
Samelson, L. E., 2645
Sanavio, Fiorella, 2397
Sanchez-Madrid, Francisco, 611, 1182
Sanders, Sheila K., 370
Sandrin, Mauro S., 546
Sanker, Albert J., 1252
Santaella, Maria, 899
Santoli, Daniela, 736
Santoro, Thomas J., 265, 2789
Sarin, Prem, 2021
Sasasuki, Takehiko, 158
Sasazuki, Takehiko, 2524
Savage, Douglas M., 806
Saxon, Andrew, 2273
Scala, Giuseppe, 1160
Scearce, Richard M., 1195
Schaefer, Mary, 633, 2107
Schaffner, Andreas, 450
Scharfstein, Julio, 972
Scher, Irwin, 2226, 2468
Schleimer, Robert P., 1936
Schlossman, S. F., 232
Schlossman, Stuart F., 186, 244, 1167, 1209, 1762, 2038
Schmid, D. Scott, 479
Schmidt, Heike, 520

Schmitt-Verhulst, Anne-Marie, 1073
Schnaper, H. William, 2301
Schrader, John W., 282, 788, 923
Schreiber, Robert D., 311, 826, 1038, 1930, 2117
Schroer, J. A., 2868, 2882
Schulman, Edward S., 1936
Schultz, Richard M., 311
Schumacher, Kurt, 2427
Schwartz, Benjamin D., 845, 1344, 2458
Schwartz, Robert S., 2232
Schwartz, Ronald H., 319, 2645
Schwartz, Stanley A., 1849
Schwarzbaum, Shelley, 674
Scott, Charles F., Jr., 2184
Scott, David W., 587, 2122
Scott, Mitchell G., 2458
Scott, Phillip, 966
Scott, Philip A., 1496
Scovern, H., 2687
Seager, Janet, 2368
Seaman, W. E., 2953
Segal, David M., 388
Segall, Miriam, 1318
Seidman, J. G., 2025
Sékaly, Rafick P., 1085
Selgrade, M. K., 3032
Sell, Stewart, 2595
Semenzato, Giampietro, 2046
Sendo, Fujiro, 2508
Sewell, W. A., 2983
Shah, Virendra O., 1780
Sharma, Somesh D., 125, 458, 977
Sharp, Shannan, 378
Shaw, Stephen, 152
Sheppard, Haynes W., 1496
Sher, Alan, 962, 966, 1460, 1511
Sherman, Linda A., 1635
Sherwin, Stephen A., 503
Shevach, E. M., 2868
Shih, Chiu-Yang, 2050
Shimonkevitz, R. P., 2814
Shin, Hyun S., 2362
Shin, M. L., 778, 892
Shin, Moon L., 1411
Shinitzky, Meir, 1356
Shiori-Nakano, Kohei, 238
Shipp, Margaret A., 2458
Shirley, Pamela S., 2104
Shulman, E. S., 2965
Sigal, Nolan H., 1889
Sihvola, M., 658
Silverman, G. A., 2651, 2656
Simmons, Richard L., 617
Simpson, Andrew J. G., 962
Sinclair, Gary D., 2246
Singer, Alfred, 1650
Singer, Dinah, 962
Singhal, Sharwan K., 762
Siraganian, Reuben R., 911
Siskind, Gregory W., 882
Sitkovsky, Michael V., 2477
Sitrin, Robert D., 1626
Sjöquist, John, 1920
Skaletsky, Eileen, 2595
Skamene, E., 948
Skamene, Emil, 1966
Skubitz, Keith M., 1882
Slapsys, Renata M., 540
Slavin, Shimon, 1108
Smathers, Patricia A., 1121, 2789
Smith, Deirdre L., 1784
Smith, Howard R., 1257
Smith, J. B., 533
Smith, J. L., 3058
Smith, Joanne, 2107
Smith, Kendall A., 1808
Smith, Phillip D., 2004
Snoddy, Susan, 869
Sobotka, Cynthia, 2533
Soldateschi, Dario, 1707
Solomon, Alan, 1322, 2490
Somers, Scott D., 2086
Sondel, Paul M., 165
Sontheimer, Richard D., 2101
Sorvillo, John, 1400
Sowder, Raymond C., 810
Spellman, Craig W., 514
Sperling, Richard, 882
Spiegelberg, H. L., 2772, 3001
Spits, Hergen, 201, 678, 2032
Splitter, Gary A., 57
Springer, Timothy A., 611, 1182
Spruance, S. L., 2827
Spurling, A., 2837
Sredni, Benjamin, 915
Stadler, Beda M., 911
Stamers, A. Tench, 1843
Stanton, G. John, 1554
Stastny, Peter, 666
Steele, Russell W., 1011
Steinberg, Alfred D., 265, 1121, 1257, 1762, 2784, 2789
Steinberg, E. B., 2789
Stein-Streilein, Joan, 1748, 2699
Stephany, David A., 1356
Sterkers, G., 2735
Sterzel, B., 2830
Stevenson, F. K., 3058
Stevenson, G. T., 3058
Stevenson, H. C., 2821
Stewart, Stanford J., 1876
Stinson, M. W., 3021
Stites, Daniel P., 491
Stoeck, Michael, 1433
Stohrer, R., 1375
Storrs, S. Bradley, 416
Strayer, David S., 2595
Streilein, J. Wayne, 2587, 2670, 2903
Strominger, Jack L., 334, 1182, 1195, 1312, 2935
Strong, Douglas M., 503, 2021
Stuart, J. M., 2995
Studer, S., 2714
Suciu-Foca, N., 2890
Suemura, M., 2751
Sugamura, Kazuo, 1611
Sullivan, Gail, 1784
Sullivan, Timothy J., 1096
Sultzer, Barnet M., 2494
Sundick, Roy S., 1252
Sundsmo, John S., 886
Surratt, R. Stephen, 1344
Sutton, Vivien R., 1363
Suzuki, Naoyoshi, 1527
Swain, Susan L., 2210
Swanson, John, 1443
Swanson, R. N., 3006, 3014
Swiedler, Stuart J., 352
Sy, Man-Sun, 30, 2184
Szakal, Andras K., 1714
Szuro-Sudol, Anna, 384

Tachibana, Takehiko, 2059
Tada, Tomio, 1646
Tagliabue, Aldo, 1707
Taguchi, Masaaki, 2307
Takada, Shinsuke, 753
Takahashi, Yuzo, 175, 3085
Takatsuki, Kiyoshi, 1246
Taketani, S., 2935
Talle, Mary A., 1754
Talle, Mary Anne, 152
Tan, Eng M., 269
Taniguchi, Noboru, 731
Taniyama, Tadayoshi, 1032
Targan, Stephan R., 1149, 2705, 2710
Tax, Wil J. M., 86
Taylor-Papadimitriou, Joyce, 508
Teale, Judy M., 2170
Tedder, Thomas F., 684
Teh, Hung-Sia, 1827
Telen, Marilyn J., 1195
Tempelis, Laurence D., 2050
Teodorescu, Marius, 1189
Terhorst, Cox, 851
Terhorst, Cox P., 2032
Teshigawara, Keisuke, 303
Tetta, Ciro, 2397
Tew, John G., 1714
Tharp, Michael D., 1096
Theoharides, T. C., 2687
Thiele, Dwain L., 2282
Thomas, James W., 701
Thomas David W., 2110
Thompson, Allan, 678
Thompson, Linda, 762, 2772, 3001
Thorbecke, G. J., 1698, 2254
Thorpe, Ruth N., 2392
Tigelaar, Robert E., 1096
Ting, Chou-Chik, 1734
Tobias, Peter S., 1913
Todd, Edward, 195
Todd, Robert F., 1209
Toivanen, Auli, 9, 120
Tokunaga, Tohru, 1032
Tomaselli, Kevin J., 2038
Tominaga, Akira, 1728
Tomonari, Kyuhei, 1641
Tompkins, W. A. F., 622
Tompkins, Wayne A. F., 2545
Townes, A. S., 2995
Triche, T., 388
Trinchieri, Giorgio, 223
Troye-Blomberg, Marita, 2000
Truffa-Bachi, Paolo, 1492
Truitt, Robert L., 2050
Tsokos, George C., 1797
Tsurufuji, Makoto, 30, 2184
Tucci, Antonietta, 2416
Tucker, P., 3049
Turgiss, Lynn R., 1539
Turpen, James B., 2262
Tutt, A. L., 3058

Uchino, Haruto, 1246, 2307
Ueda, Yuji, 753
Uede, Toshimitsu, 1090
Ulevitch, Richard J., 1913
Umiel, T., 232
Uwadana, Naoto, 731
UytdeHaag, Fons G. C. M., 1234

Vadas, M., 2983
Vainio, Olli, 9, 3036
van Asten, Jack A. A. M., 1234
van de Rijn, Matthijs, 2032
van de Rijn, Mattijs, 851
van der Marel, Pieter, 1234
Van Epps, Dennis E., 697
van Es, Leendert A., 1924
Vanguri, P., 778
van Oudenaren, Adrianus, 1625
van Steenis, Bert, 1234
Varitek, Vincent A., Jr., 275
Vasil, Adriana, 794
Vaux, D. L., 554
Venge, P., 2977
Verhoef, Jan, 125
Vilcek, J., 2821
Villalta, Fernando, 1504
Virtanen, I., 2695
Vitetta, Ellen S., 1108, 2204, 3049
Vitiello, Antonella, 1635
Volanakis, John E., 2411
von Steldern, Dirck, 1350
Vucak, Ivica, 325
Vyth-Dreese, Florry A., 201

Wahl, Larry M., 911
Wahl, S. M., 2853
Wahlgren, Mats, 2000
Wählin, Birgitta, 2340
Waite, Moseley, 2104
Wakeland, Edward K., 2432, 3052
Waldmann, Thomas A., 690, 2046
Waldrep, J. C., 2746
Waldschmidt, Thomas J., 2204
Wall, Katherine A., 1056, 2445
Wall, Randolph, 2273
Wang, Chang Y., 536
Wang, Chang Yi, 2356
Wang, Lai C., 536
Ward, Jerrold M., 132
Ware, Carl F., 334, 1182, 1312
Warner, Noel L., 212, 514, 1789
Warnke, Roger A., 212
Warr, Gregory W., 1582
Warren, Hilary S., 1771
Warren, Keith A., 1443
Warrington, Richard J., 298
Wass, J., 2837
Wasserman, Stephen I., 934
Watanabe, Takeshi, 1294, 2989
Watson, Andrew J., 1622
Watson, James D., 288, 491, 1289
Watson, Susan R., 984
Ways, Judy P., 856
Webb, D. R., 2843, 2848
Wechsler, Andrew S., 773
Weigle, William O., 2258
Weiner, Howard L., 1178
Weiner, Roy S., 1780
Weinstock, Joel V., 959, 2529
Weintraub, J., 1522
Weirnik, Peter, 503
Weiss, P. N., 2827
Weissman, Irving L., 64
Welsh, Raymond M., 991, 1531, 1539
Welte, Karl, 806, 2356

Wettstein, Peter J., 471
Whalen, Robert G., 2267
White, Janice, 794
Whitehead, Alexander S., 2416
Whitlow, Michael B., 1411
Wicker, Linda S., 2468
Widmer, Michael B., 2135
Wilburn, Shannon, 1201
Wilde, David B., 2178
Wilkins, John A., 298
Wilson, Curtis B., 1268, 2781
Wilson, D. B., 2805
Wilson, James G., 684
Wirth, J. J., 3028
Witte, P. L., 2903
Woda, Bruce A., 1531, 1917
Wolf, Benjamin, 1860
Wolf, David, 329
Wong, Grace H. W., 788
Wood, Gary S., 212
Woodruff, Judith J., 1368
Woods, Derek E., 2416
Word, C., 3049
Wu, Shaokee, 2110
Wunderlich, John R., 1356

Xue, B., 1698

Yachie, Akihiro, 731
Yamamoto, Hidehiko, 651
Yamamura, Yuichi, 1961, 2751
Yang, Hyekyung, 622, 2545
Yarchoan, Robert, 1222
Yasukawa, Masaki, 2011
Yee-Foon, Juanita, 1860
Yip, Y. K., 2821
Yodoi, Junji, 303, 1246
Yoshimura, T., 2989
Young, Robert N., 429
Yowell, Robert L., 543
Yu, A. L., 2762
Yu, J., 2762
Yu, Margaret, 1827

Zacharchuk, Charles M., 2362
Zacheis, Michelle P., 845, 1344
Zan-Bar, Israel, 1683
Zanetti, Maurizio, 1268, 2452, 2781
Zarling, Joyce M., 1017, 2011
Zeiger, R. S., 2772, 3001
Zerivitz, Kenn, 329
Zerubavel, Rachel, 2316
Zigmond, S. H., 940
Zilber, Marie-Thérèse, 2551
Zinkernagel, R. M., 475
Zipf, T. F., 3064
Zitron, I. M., 533
Zlotnik, Albert, 794, 2814
Zubler, R., 1522
Zvaifler, Nathan J., 768
Zweerink, Hans J., 429

U.S. Postal Service

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION

Required by 39 U.S.C. 3685)

1A. TITLE OF PUBLICATION	1B. PUBLICATION NO.	2. DATE OF FILING
Journal of Immunology	0 0 2 2 1 7 6 7	10/1/83
3. FREQUENCY OF ISSUE: Monthly	3A. NO. OF ISSUES PUBLISHED ANNUALLY: 12	3B. ANNUAL SUBSCRIPTION PRICE: $130.00

4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION *(Street, City, County, State and ZIP Code) (Not printers)*
428 East Preston Street, Baltimore, Maryland 21202

5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OF GENERAL BUSINESS OFFICES OF THE PUBLISHER *(Not printer)*
428 East Preston Street, Baltimore, Maryland 21202

6. FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR *(This item MUST NOT be blank)*

PUBLISHER *(Name and Complete Mailing Address)*
Williams & Wilkins Co., 428 East Preston Street, Baltimore, MD 21202

EDITOR *(Name and Complete Mailing Address)*
Joseph D. Feldman, M.D., Scripps Clinic and Research Foundation, La Jolla, CA 92037

MANAGING EDITOR *(Name and Complete Mailing Address)*

7. OWNER *(If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed.)*

FULL NAME	COMPLETE MAILING ADDRESS
American Association of Immunologists	9650 Rockville Pike Bethesda, MD 20814

8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES *(If there are none, so state)*

FULL NAME	COMPLETE MAILING ADDRESS
None	

9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES *(Section 423.12 DMM only)*
The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes *(Check one)*

[X] (1) HAS NOT CHANGED DURING PRECEDING 12 MONTHS
[ ] (2) HAS CHANGED DURING PRECEDING 12 MONTHS *(If changed, publisher must submit explanation of change with this statement.)*

10. EXTENT AND NATURE OF CIRCULATION	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES *(Net Press Run)*	8666	9000
B. PAID CIRCULATION 1. Sales through dealers and carriers, street vendors and counter sales	NONE	NONE
2. Mail Subscription	6791	7806
C. TOTAL PAID CIRCULATION *(Sum of 10B1 and 10B2)*	6791	7806
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	193	197
E. TOTAL DISTRIBUTION *(Sum of C and D)*	6984	8003
F. COPIES NOT DISTRIBUTED 1. Office use, left over, unaccounted, spoiled after printing	1682	997
2. Return from News Agents	NONE	NONE
G. TOTAL *(Sum of E, F1 and 2--should equal net press run shown in A)*	8666	9000

11. I certify that the statements made by me above are correct and complete

SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER
Publisher

PS Form 3526 July 1982 *(See instruction on reverse)*

THE JOURNAL OF IMMUNOLOGY
Copyright © 1983 by The American Association of Immunologists
Vol. 131, No. 6, December 1983
Printed in U.S.A.

SUBJECT INDEX TO VOLUME 131

Abortion, clonal, T cell precursors, 1688
Accessory cell
  differential requirements, T cell activation, 2714
  function failure, virus tolerance and, 16
  function of endothelial cells, antigen presentation by, 666
  I-A$^+$, immune suppression, 1728
  Ia determinants, self-recognition, cytotoxic T lymphocyte responses and, 1650
  L-leucine methyl ester sensitivity, phenotype, 2282
  T cell responses to *Mycoplasma arthritidis*, control of, 1702
Acetylation, cytochrome c, superoxide anion production, alveolar macrophages, 2104
Aβ Chain, Ia, gene, polymorphism surrounding, 2025
Actin
  lymphocyte cell surface molecule antigenically related to, 370
  Thy-1.2 and, serologic relatedness, monoclonal antibody and, 1332
Adenosine 3′:5′-monophosphate, lymphocyte responsiveness to, changes, 2945
Adhesion molecule, lymhocyte, lymph node high epithelium recognition by, 1368
Aging
  cytotoxic T lymphocyte, precursor frequency, 2215
  peripheral lymphocytes, unusual pattern of surface marker expression, 191
Aleutian disease, progressive, virus-specific lymphocyte response, 1558
Allergen, ragweed pollen, isolation and properties, 706
Allergy, contact, dinitrofluorobenzene, desensitization, 2682
1-*O*-Alkyl-2-acetyl-*sn*-glyceryl-3-phosphorylcholine, platelet-activating factor, release from mast cells, 2958
Alloantigen
  acquired immunologic hyporesponsiveness, maternal influence, 1115
  concanavalin A or, interleukin 2 release stimulated by, 1274
  cytotoxic and suppressor T lymphocytes specific for, subdivision, 2296
  immune response to, regulation, 1065
  intracamerally induced suppression, delayed-type hypersensitivity, 2669
  MB1/MT1 and DR1, dissociation of expression in cell mutants, 1318
  natural killer, cytotoxic T lymphocytes, 1391
  suppressor T cells specific for, allopregnancy and, 638
  T cell unresponsiveness to, spleen cells, clonal analysis, 2165
Alloantisera, T cell clone-specific, antigen-induced T cell activation, 2645
Allogeneic effect factor, Lyb5$^+$ and Lyb5$^-$ B cell activation, thymus-dependent and -independent antigens, 2246
Allograft
  bone marrow, recipient, interleukin 2 and, 1771
  skin, monoclonal antibodies and, 86
  sponge matrix, cytotoxic T cell maturation within, 617
Alloimmunization, T lymphocytes induced by, reactions against leukemia, 2050
Allotype
  gene linked to
    antibody responses, tobacco mosaic virus protein, 2875
    anti-phosphorylcholine response phenotype, 1570
  Gm(st), γ3 myeloma protein, 1865
  immunoglobulin κ-light chain, splenic mRNA analyses, 1000
  latent, γ-chain, 1860
Amastigote, *Leishmania donovani*, survival in monocytes, 1994
Amine, biogenic, leukotrienes and, respiratory responses, 434
Amyloid, P-component, inhibition of platelet activation by, 1416
Anaphylaxis, slow-reacting substance of, measuring leukotrienes of, 429
Androgen, receptors, absence, OKT8-positive cells, 2767
Anemia, hemolytic, monocyte Fc receptors in, 1240
Angiotensin, liver granuloma, *Schistosoma mansoni*, 2529
Antagonist
  calmodulin, T cell mitogenesis inhibition, 2291
  lipoxygenase, natural killer inhibition by, 2953
Antibody
  anti-δ, effects on immune system, necrite, 593, 601
  anti-γ, differentiative response to, 98
  anti-μ, lymphoma induced by, athymic, 2069
  anti-arsonate, fine specificity and isotype heterogeneity, 1889
  anti-asialo GM_1, tumor cell clearance and, 1024
  anti-*p*-azophenylarsonate, cross-reactive idiotype associated with, idiotypic heterogeneity, 423
  anti-histone, *in vivo* and *in vitro* production, 269
  anti-idiotope, isolation of isotype variants by sequential sublining, 877
  anti-idiotype
    anti-α1→3 dextran response, analysis, 1375
    autoimmune tuberlointerstitial nephritis and, 1268
    HLA-DR4 and DR2, 2890
    immune complex glomerulonephritis, participation in, 2780
    immunity against trypanosomes, 1511
    immunotherapy with, B cell tumor, 1600
    polyvalent epitope and, effect on idiotype suppression, 13
    syngeneic, monoclonal anti-HLA-DR antibodies and, 1339
  anti-Ig, insolubilized, Lyb-5$^-$ cells stimulated with, 2107
  anti-IgD, immune defective B cells, activation by, 2226
  anti-Leu-4, T cells reacted with, internalization of p22,28 complex, 536
  anti-leukocyte, Fc receptor blockade by, 140
  anti-Leu-3/T4, reaction with monocyte/macrophage and Langerhans lineage, 212
  anti-neutrophil, neutropenia induced by, effect on late phase reactions, 929
  anti-nucleoside-specific, selective inhibition by nucleoside-ricin A conjugate, 1762
  anti-Tac, interleukin 2 receptor blockade by, 690
  cross-reacting
    anti-idiotypic, rheumatoid factors, IgG in, 719
    vaccinia and intermediate filaments, 1546
  cutaneous basophil hypersensitivity, mediation by, 2675
  humoral response, viral proteins, cytomegalovirus, 3032
  IgE, immunity against *Schistosoma mansoni*, 1460
  IgE myeloma protein, idiotypic determinant detection by, 3001
  IgM and IgG, *Toxoplasma gondii* antigen recognition by, 977
  intact and pepsin-digested, inhibitory activity to Ia-like determinants, 725
  interleukin 1, immunoadsorbent for purification, 1834
  killing dependent on, *Cryptococcus neoformans*, 1455
  light chain idiotypes, neoplastic B lymphocytes, detection and destruction, 3058
  liposomes bearing, T-independent antigen mobility on, 2924
  pneumonitis mediated by, platelet-activating factor and, 1802
  production, cord blood lymphocyte function in, 1222
  production suppression, T cell activation of Ly-23 effectors, 2154
  recognition of *I-A* mutant, idiotypic and fluorometric analysis, 359
  resistance mechanisms dependent on, athymia and *Schistosoma mansoni* infections, 1475
  response
    antigenic determinant, tobacco mosaic virus protein, 2874
    influenza virus, fine specificity, 1229
    rabies-specific, 1234
    thymus-independent antigens, *Leishmania tropica* infection and, 1492
  secretory, Peyer's patch cells primed for, 2616
  specificity, degeneracy of, 882
  synthesis, B cell function, host-vs-graft disease, 2623
  teratocarcinoma antigens, vasectomy sera, 2908
  thymosin β_4, production and characterization, 821
  toxin and, hybrid, target cell killing, 3091
  trinitrophenyl-*Brucella abortus* and -Ficoll, responses to, 633
  Trypanosoma cruzi antigen defined by, 972
Antibody-antigen complex, circular, monoclonal antibodies to human chorionic gonadotropin and, 1900
Antibody-dependent cellular cytotoxicity
  mechanisms of macrophage cytotoxicity, 1438
  monocyte subsets as effector cells in, 1780
  natural killer activity and, inhibition by lipomodulin, 662
  tumor targets, IgG monoclonal antibodies and, 1028
Antigen
  see also specific type and site
  antibody response specific for, rabies virus, 1234
  arthritis suppression specific for, immunity and, 2995
  B cell clones stimulated by, isotype expression, T cell regulation of, 2170
  B cell function, host-vs-graft disease, 2623
  B lymphocyte-associated (B4), expression on B lymphocytes, 244
  B lymphoma cell, processed antigen, 2726
  C4, complement secretion by surface C4-positive macrophages, 2420
  class I histocompatibility, interleukin 2-secreting T cell hybridoma responding to, 1656
  class of response induced by, lymphocyte interactions determining, 1103
  cobra complement factors C3 and cobra venom factor, relationship between, 1920
  cytotoxicity nonspecific for, sodium periodate-modified cytotoxic T lymphocytes and, 1426
  determinant, *see* Determinant
  gp130, melanoma, 1595
  H-2D region-associated, different H-2 haplotypes, 2440
  herpes simplex virus, cellular interactions, cytotoxic T lymphocyte response, 479
  ingested, lymphoproliferative responses suppressed by, 2651
  Leishmania donovani, recognition by T lymphocyte lines and clones, 1496
  Leu-4, processing and translation, 1876
  Leu-7 and Leu-11, natural killer subset definition, 1789
  leukemia-associated, characterization, 2038
  lymphocyte function-associated 1, immunochemistry, 1182
  lymphomamagenesis induced by, B cell lymphoma with known antigen specificity, 2064
  macrophage activation specific for, schistosomiasis and, 1481
  major histocompatibility complex class I, thymic differentiation markers T6 and M241, 851
  non-parasite, suppression of IgG production to, *Trypanosoma cruzi*, 1978
  p80, medullary thymocytes, 1195
  peptide, T lymphocyte response to cytochrome *c*, 319
  persisting cell precursors and mast cells induced by, 923
  Peyer's patch cells primed with, immune responses and secretory antibody production, 2616
  platelet-activating factor release initiated by, mast cells, 2958
  presentation
    endothelial cells, 666
    induction, P388D1 cells, 2814
  presentation by monocytes, stimulant processing and interleukin 1 requirement, 1160
  Qa-m9, description, 1363
  Qa-m7 and Qa-m8, definition by monoclonal antibody, 546
  reactivity, T cells acquiring, 1688

Antigen—*continued*
recognition by antibody OKT8, expression by natural killer, killer, and cytotoxic T cells, 223
regulation, B cell chronic lymphocytic leukemia, 2046
responsiveness, cytotoxic T lymphocyte hybridomas capable of, 50
restriction specificity, male-specific T cell lines, 1641
retinal, experimental autoimmune uveitis, 259
retroviral envelope, lymphoid cells, 3036
SB, proliferation blocking, OKT4 antibodies, 152
schistosomiasis, phenol sulfuric test active peak, clearance, 2520
self, cytotoxic T lymphocyte generation suppression, 45
Sm/RNP, intact, isolation from thymus, 347
stage- and species-specific determinants, *Leishmania tropica* monoclonal antibodies, 1987
strength and memory, distinguishable sites affecting, peptide antigen, 319
suppressor cells specific for, generation, 1209
surface, B cell, hybridomas and, 98
T cell activation induced by
clone-specific alloantisera, effects, 2645
requirements, 23
T cell lines and clones specific for, interferon production and proliferation, 1049
T cells specific for, delayed-type hypersensitivity and, 77
thymus-dependent and -independent
B cell memory development, 567
functional heterogeneity of memory B lymphocytes, 561
Lyb5$^+$ and Lyb5$^-$ B cells responding to, allogeneic effect factor, 2246
receptor cross-linking, B cell activation, 2641
thymus-independent
B cell response requirements, 1131
response in *Leishmania tropica* infections, 1492
thymus-leukemia, structural identity of homologues, 1344
T-independent
mobility on antibody-bearing liposomes, 2924
tolerogenicity and immunogenicity, 2196
Toxoplasma gondii, Western Blot analysis, 977
viral, *H-2*-restricted cytolytic T lymphocyte, identification by, 2551
Antigenicity, C-reactive protein, lymphocytes, 2930
Arachidonate, metabolism, lipid bodies and, macrophages and mast cells, 2965
L-Arginase, liver, liver-derived inhibitory protein, 2427
Arginine, serine enzyme specific, B cell activation, 2494
Arsonate, antibodies against, fine specificity and isotype heterogeneity, 1889
Arthritis, collagen-induced, antigen-specific suppression, 2995
Asialo GM_1, antigen against, graft-*vs*-host disease prevention, 2101
Asialo GM_2, Hodgkin's disease and, 1591
Athymia
congenital, *Schistosoma mansoni* infections and, 1466, 1475
lymphoma and, anti-μ-induced, 2069
Atopia, Tϵ and Tγ cells, characterization, monoclonal antibodies, 2772
Autoantibody
glomerulonephritis and, B cell hyperactivity, 2232
hybridoma synthesizing, vaccinia infection and, 1546
IgM_K, association of λIIIb light chains with, 1322
natural, hybridomas secreting, 2267
rheumatoid factor, anti-idiotypes to, 719
Autoimmunity
acute leukemia and, surface antigen T305 found in, 762
defective B cell tolerance induction, mouse strains, 2630
encephalomyelitis, determinant-specific vaccination against, 2810
experimental autoimmune uveitis, retinal antigens in, 259
hemolytic anemia, monocyte Fc receptors in, 1240
hyperactivity and, B cell, 2232
immune complex, abnormal binding to hepatic nonparenchymal cells, 2784
immune complex disease and, neonatal induction of transplantation tolerance and, 251
immune interferon production and, 265
thyroiditis
serum thyroglobulin levels, 1252
thyroglobulin-specific T lymphocyte line, vaccination, 2316
tubulointerstitial nephritis, anti-idiotype in, 1268
Azophenylarsonate, repertoire expression specific for, regulation, 1889
p-Azophenylarsonate, antibody against, cross-reactive idiotype associated with, idiotypic heterogeneity, 423

Bacillus Calmette-Guérin, *Mycobacterium bovis*, mechanism of genetic resistance to, 1966
Bacteria
membrane components, IgG subclass responses to lipopolysaccharide and, 6
serum resistance in, mechanism, 1443
Basophil
cutaneous, antibody-mediated hypersensitivity, 2675
leukemia cells
cell cycle-associated changes in histamine release from, 911
fate of IgE bound to, 388
receptors on, dissociation of IgE from, 1949
B cell
activation, serine protease, 2494
activation and proliferation, interleukin 1 effects on, 801
antigen-binding, membrane depolarization, 2641
antigen-presenting, requirement for activation, 109
antigen-stimulated clones, isotype expression, T cell regulation of, 2170
bystander, activation requirements, 581
chronic lymphocytic leukemia, antigen regulation, 2046
colony-forming, hapten-specific, subpopulation delineation, 587
defective
deleted X chromosome and, 1218
macrophage independence, 2630
depletion, ocular herpes simplex virus and, 1554
destruction, T cell-derived factors and, 1609
determinant, myelin basic protein, 275
differentiation
immunoglobulin isotype diversity, 1693
lack of environmental effect on, 9
molecular aspects, presidential address, i
pokeweed mitogen-induced, suppression by natural killer cells, 651
T cell factor-induced, 1306
differentiation antigen, DR-related, 2458
differentiation factors, T cell-derived lymphokines containing, γ-specific mRNA and, 3049
donor, host-*vs*-graft disease, 2623
Epstein Barr virus-induced proliferation, impaired regulation by rheumatoid arthritis lymphocytes, 768
Epstein Barr virus-induced responses, systemic lupus erythematosus, 1797
growth and differentiation factor, interleukin 1 and, WEHI-3 cell line, 1289
growth factor, biochemical and physicochemical characterization, 1838
hapten-specific, cloning efficiencies, 554
hybridoma, common variable immunodeficiency, 2273
hyperactivity, autoimmunity and, 2232
immune defective, anti-δ activation of, 2226
immunoglobulin C and V gene expression, frequency analysis, 1629
insulin receptor genesis, T cell cooperation for, 644
Lyb-5$^-$, stimulation, insolubilized anti-Ig antibodies, 2107
Lyb5$^+$ and Lyb5$^-$, activation, response to thymus-dependent and -independent antigens, 2246
Lyb-5$^+$ and Lyb-5$^-$, asymmetry in idiotype-isotype expression, phosphocholine and, 2468
lymphoblastoid line, immunoglobulin secretion by, suppression, 298
lymphokine derived from, regulatory function of Thy-1$^-$ cells, 1283
lymphoma
known antigen specificity, 2064
processed antigen, 2726
memory
development, differential sensitivity to stimulation with thymus-dependent and independent antigens, 567
germinal center generation of, 2254
mitogen-stimulated response, accessory cell phenotype, 2282
phosphorylcholine binding, non-immunoglobulin molecules, 365
phytohemagglutinin-induced differentiation, T cell suppression of, 1214
proliferation, two subtypes of leukocyte interferon, 238
γ-specific mRNA, differentiation factors specific for, 3049
splenic, viral antigen display by, 3078
subpopulations, anti-δ suppression effects on, neonate, 593, 601
subset modulation, total lymphoid irradiation and, 1683
thymic-independent antigens, responses to, 1131
tolerance, haptenated immunoglobulins inducing, 2204
tolerization, macrophages, 2122
tumor, immunotherapy with anti-idiotypes, 1600
Bence Jones protein SUT, λVI light chain, region sequence, 2490
Binding assay, monoclonal antibodies and, antigenic structure of HLA-A2, 856
Binding factor, IgA, formation by T cell hybridoma, 303
Binding site, vasoactive intestinal polypeptide, peripheral blood lymphocytes, 1173
Bladder, carcinoma cells, altered cell surface antigen expression, 3073
Blastogenesis, lymphocyte, mast cell granule effects on, 1942
Blockade
antibody, suppressor T cells, 1646
antigen-specific proliferation, lymphokine release, and T lymphocyte binding, monoclonal antibody GK1.5, 2178
autologous mixed lymphocyte reaction, T helper cell-specific monoclonal antibodies, 2323
Fc receptor, anti-leukocyte antibody, 140
interleukin 2 receptor, anti-Tac antibody, 690
lymphoproliferation, monoclonal antibodies, 2735
monoclonal antibody, *Plasmodium gallinaceum* gametes, 2557
natural killer cell lysis, functionally distinct epitopes of T-200 and, 1742
reovirus, monoclonal anti-idiotype antibody, 2535
Blood
cord, lymphocytes, function in antibody production, 1222
lymphocyte, fine specificity of antibody response to influenza virus, 1229
peripheral
epinephrine-induced changes in lymphocyte subsets, 1178
T and B cell responses to, accessory cell phenotype, 2282
peripheral leukocyte, spontaneous interferon production, herpes labialis, 2827
peripheral lymphocytes
oligoclonal cerebrospinal fluid, multiple sclerosis, 2328
rabies-specific antibody production, 1234
vasoactive intestinal polypeptide receptors on, 1173
peripheral mononuclear cells, lack of pokeweed mitogen-induced IgE formation, 3001
Blood island, ventral, hemopoietic cell ontogeny, 2262
B lymphoblast, T lymphoblast and, deoxyadenosine production, 1776
B lymphocyte
activation, serine protease, 2494
antigen associated with (B4), expression on B lymphocytes, 244
antigen-binding, decrease in plasma membrane potential of, 2641
chronic and acute lymphocytic leukemia and, monoclonal antibody detecting 39,000 m.w. molecule, 3064
depletion, ocular herpes simplex virus and, 1554
hapten-specific, cloning efficiencies, 554
immune defective, anti-δ activation of, 2226
lineage cells, regulatory disorders, neonate, 2219
memory, functional heterogeneity, 561
monoclonal antibodies, generation and characterization, 1754
monocyte-independent stimulation, phorbol myristate acetate, 2279
monocytes, non-B lymphocytes, and, unique Fc, of, 378
neoplastic, detection and destruction, antibodies against light chain idiotypes, 3058

precursor, phenotypic and functional characterization, fetus and adult, 572
receptor, interferon-α/β induction, 1895
T lymphocyte and, Thy-1 antigen on, 2903
X-linked immunodeficiency, lymphokine-induced responses to trinitrophenyl-Ficoll, 1698
Bone marrow
allograft recipient, interleukin 2 and, 1771
histamine-containing cells cloned from, mucosal mast cells, 915
long-term cultures, B lymphocyte precursors in, 2240
mast cells derived from, platelet-activating factor release, 2958
pre-B cell kinetics, cytoplasmic μ-chain-bearing cells, 2635
resistance to, characterization of effector cells, 92
T cell precursors, clonal abortion, 1688
thymus-homing cells, characteristics, 64
thymus leukemia-bearing cells, expression, total lymphoid irradiation and, 1683
transplantation, interleukin 2 production after, 1205
Brucella abortus, trinitrophenyl and, antibody responses to, 633
Bursectomy, incubation and, immune capacity, 120

Calcium, T cell mitogenesis inhibition, calmodulin antagonists, 2291
Calmodulin, antagonist, T cell mitogenesis inhibition, 2291
Cancer
see also specific site and type
lung, non-small cell, p31 on, 497
tumor-derived cells, suppression of lymphocyte responsiveness by, 3085
Carbohydrate, streptococcal group A, monoclonal antibodies to, 1326
Cathepsin H, cleavage of C5 by, 397
Cell
see also specific type and site
antigen-modified syngeneic, parenteral injection of, T cell responses, 77
antigen-presenting, B cells as, 1909
influenza-infected, recognition by cytolytic T lymphocytes, 1635
interleukin 2-responsive, ontogeny, fetal thymus, 533
nonphagocytic, immune complex transport to lymph node follicles, 1714
OKT4$^+$ and OKT8$^+$, abnormal suppressor T cell subsets in systemic lupus erythematosus, 753
proliferation, mitogen-induced, bursectomy and incubation, 120
sorting, fluorescence-activated, instructor cell for monocyte procoagulant activity, 749
thymus leukemia-bearing, total lymphoid irradiation and, 1683
tumor-derived, suppression of lymphocyte responsiveness by, 3085
Cell cycle
histamine release changes associated with, basophilic leukemia cells, 911
status, thymus organ cultures, 1085
Cell line
allo-Ia-reactive T cell line, T cell clonal expansion and, 37
alloreactive, lectin-stimulated interleukin 2 release, 1274
B
B cell differentiation factor-stimulated, phospholipid methylation, 1961
Epstein Barr virus-transformed, malaria and, 2000
B and T, complement activation by, 1396
B lymphoid, macrophage, and myeloid, Ia and H-2 antigen induction by γ-interferon, 788
HLA-A2, recognition of HLA-A2 mutant and variant target cells by, 1312
Hodgkin's disease, asialo GM_2 on, 1591
J774.2, Ia-restricted antigen presentation by, 674
leukemic, mixed lymphocyte reaction stimulatory ability of mature myelomonocytic cells, 736
lymphoblastoid
dissociation of DR and MB/MT expressions in mutants, 1318
Dw/LD, DR4 β-chain polymorphisms, 1622
macrophage, Ia and H-2 antigen induction on, immune interferon, 315
nucleated, U937, complement channel elimination from, 1411
OKT8$^+$, DC-specific cytolytic T lymphocyte, 2777
optimal, hybridoma development, 1201
T
antigen-specific, 1641
continuous, antitumor immune response suppression by, 514
interferon production by, 1611
tumor, Ia$^+$, T cell activation and, 2714
U937, surface antigens of, 743
WEHI-3, B cell growth and differentiation factor co-purifying with interleukin 1, 1289
Cell membrane
C1q binding and C1 activation by, 416
Ia molecules, differentiation of B cell hybrids and, 98
Cell sorting, fluorescence-activated, surface C4-positive macrophage isolation by, 2420
Cell-stimulating factor, histamine-producing, homogeneous interleukin 3, 282
Cell surface, determinant expression, changes, lipid modulating agents and, 1356
Cell surface antigen
altered expression, bladder carcinoma cells, 3073
cytolytic T lymphocyte-target interaction, association with, 611
leukocyte, immune function and, 2913
newborn cord blood lymphocytes, T cell lymphoma virus infection, 2021
T305, acute leukemia and autoimmunity, 762
Cercariae, irradiated, mast cells and IgE in immunity against *Schistosoma mansoni*, 1460
Cerebrospinal fluid, oligoclonal, IgG idiotypes, multiple sclerosis, 2328
Chagas' disease, polymorphonuclear cells in, neutrophil interactions with *Trypanosoma cruzi*, 1504
β-Chain, DR4, polymorphisms, 1622
γ-Chain, latent IgG allotype gene products, 1860
μ-Chain, cells bearing, pre-B cell kinetics, bone marrow, 2635
Chemiluminescence
macrophage, anti-T cell monoclonal antibody-induced, 2500
neutrophil, luminol-dependent, inhibition by polyanions, 2515
Chemotaxis
leukocyte, parameters, 940
macrophage subpopulations, delayed hypersensitivity reaction sites, 2989
Chlamydia psittaci, inhibition, lymphokine γ-interferon, 2542
Choriomeningitis virus, *see* Virus
Chromosome
X, deleted, B cell function and, 1218
Y, disease related to, X-linked immune deficiency gene, 1257
Circadian rhythm, thymosin$_{\alpha 1}$, thymectomy effects, 148
Cleavage
C5
cathepsin H, 397
C5b-9 *Escherichia coli* 0111B4 bactericidal efficiency and, 2570
C6-dependent, C5, acid and, 892
particle-bound C3 products, induction of granulocyte histaminase release by, 439
Cloning efficiency, large and small B cells, 554
Cobra venom factor, cobra complement factor C3 and, antigenic relationships, 1920
Collagen, arthritis induced by, antigen-specific suppression, 2995
Colony-stimulating factor
activity, homogeneous interleukin 3, 282
interferon, interleukin 2, and, production, large granular lymphocytes, 2379
interleukin 2 and, coordinate synthesis in T cell lymphoma, 293
macrophage-type, interferon-enhanced responsiveness, 2374
purified, granulocyte function activation by, 2983
Complement
activation
C3b deposition during, 1930
C6-dependent cleavage of C5 in acid, 892
lymphoblastoid B and T cell lines, 1396
C1, activation, precursor C1s assay and, 1924
C3
cobra venom factor and, antigenic relationships, 1920
particle-bound cleavage products, histaminase release induction by, 439
C4
protein binding, genetic polymorphism, 1565
secretion, macrophages, 2420
C5, cleavage by cathepsin H, 397
C3a, peptides, suppression of immune responses, 2258
C2 and C3 convertase formation and regulation, erythrocytes, 403
C4 and Slp, comparison, 1405
C3b
binding of factors B and H to, paroxysmal nocturnal hemoglobinuria erythrocytes, 2484
deposition during activation of complement, 1930
receptor expression by T lymphocytes, 684
C5b-9
bacterial resistance to complement-mediated killing, 2563
Escherichia coli 0111B4, bactericidal efficiency, 2570
channel, elimination from nucleated mammalian cell membranes, 1411
C1q, fibronectin binding to, 1400
C1q binding and C1 activation, cellular membranes and, 416
C-reactive protein, antigenicity, lymphocytes, 2930
demyelination by, 778
factor H, factor I, and properdin factor B, interaction of C3b bound to pneumococci with, 409
killing mediated by, bacterial resistance to, 1443
leukocyte, C5 in lymphocyte stimulation, 886
receptor, expression, normal and neoplastic cells, 899
Concanavalin A
alloantigen or, interleukin 2 release stimulated by, 1274
intact and nicked fragments, effects on immune functions, 1626
spleen cell culture stimulated by, cytotoxic polymorphonuclear leukocytes induced by, 2508
suppressor/cytotoxic T cells stimulated by, helper/inducer T cell migration and, 697
T cell growth factor reactivity induced by, Lyt-2-positive T cell precursors and, 19
Contrasuppression, cyclophosphamide-sensitive, trinitrophenyl-anterior chamber-associated immune deviation, 2745
Cord blood, lymphocyte, T cell lymphoma virus-infected, antigen expression, 2021
Cortisone, cyclosporin A and, T cell deficiency in listeriosis, 450
Creutzfeldt-Jakob disease, Scrapie and, genetic control of, 491
Cryptococcus neoformans, antibody-dependent leukocyte killing of, 1455
Cyclophosphamide
contrasuppression sensitive to, trinitrophenyl-anterior chamber associated immune deviation, 2746
cytotoxic precursors resistant to, expansion by interleukin 2, 806
pretreatment, Meth A vaccines and, 2601
suppressor T cells, type III pneumococcal polysaccharide-specific, 2190
Cyclosporin A, cortisone and, T cell deficiency in listeriosis, 450
Cyclosporine, binding, lymphocytes and phospholipid vesicles, 712
Cytochalasin, effects on lymphocytes, rosette formation inhibition, 1126
Cytochrome *c*
acetylated, superoxide anion production, alveolar macrophages, 2104
T lymphocyte response to, 319
Cytolysis, tumor, sequential activation of mononuclear phagocytes for, 1038
Cytomegalovirus, *see* Virus
Cytoplasmic factor, signal-transmitting, lipopolysaccharide responsiveness of lymphocytes and, 1294
Cytoskeleton
detergent-insoluble lymphocyte matrix, lymphocyte membrane proteins and, 1917
lymphocyte, rosette receptor and, 1126
natural killer cell, polarization, target cell conjugation and, 2695
Cytosol, T cell hybridoma, antigen-specific suppressor factors, 2843
Cytotoxic factor, soluble, macrophage-mediated cytotoxicity, 2362
Cytotoxicity
antibody-dependent and immobilized immune

Cytotoxicity—*continued*
complex-dependent cellular, mechanisms of macrophage cytotoxicity, 1438
antibody-dependent cellular
inhibition by lipomodulin, 662
monocyte subsets as effector cells in, 1780
tumor targets, IgG monoclonal antibodies and, 1028
antibody-toxin hybrid molecules, target cell killing, 3091
cytotoxic T lymphocyte-mediated, lymphocyte function-associated antigen-1, 1182
granulocyte, activation, colony-stimulating factors, 2983
macrophage, mammary tumors, 2074
macrophage-mediated, soluble cytotoxic factor from, 2362
monocyte, activation, immune interferon, 2821
natural killer
depression after interferon therapy, 503
nonoxidative mechanism, 1784
natural killer cell-mediated, persistent viral infection, 991
oxidation-dependent cellular, sodium periodate-modified cytotoxic T lymphocytes and, 1426
tumor, macrophages activated for, 1032
vaccinia-induced peritoneal exudates, Thy-1.2 homologue-positive cells mediating, 2545

DC antigen, cytolytic T lymphocyte line specific for, OKT8$^+$, 2777
Decidua, uterine, suppressor cell activity, pregnancy and, 540
Demyelination, requirement of membrane attack components of complement system, 778
D-end, hyporesponsiveness induced in, hapten-specific cytotoxic T cell response, 2184
Dendritic reticulum cell, precursor, peroxidase-positive mononuclear leukocytes as, 2719
Deoxyadenosine, deoxycoformycin and, RNA synthesis inhibition, 2762
Deoxycoformycin, deoxyadenosine plus, RNA synthesis inhibition, 2762
Deoxynucleotidyl transferase, terminal, expression in thymus during ontogeny and development, 195
Dermatitis, allergic contact, pulmonary induction, 1748
Detergent, lymphocyte cytoskeletal matrix insoluble with, lymphocyte membrane proteins and, 1917
Determinant
anti-idiotypic subset, immunoenhancing T cells, tumors, 2576
binding of monoclonal antibodies to breast cells, 508
Fab, cross-reaction, T cell tumor product and, 1582
Ia
accessory cell, recognition, cytotoxic T lymphocyte responses and, 1650
circulating T cells and, tetanus toxoid, 731
Ia-like , inhibitory activity of antibodies to, 725
idiotypic
cross-reacting, polyclonal immunoglobulin, 3001
tumor immunotherapy, 1600
I-J, recognition, polysaccharide-specific T cells, cyclophosphamide and, 2190
L3T4, T cell surface molecule, identification, 2445
major histocompatibility complex and Thy-1.2, expression modification by lipids, 1356
monoclonal antibody against, proliferation of cloned T cells and, 1056
myelin basic protein
autoimmune encephalomyelitis vaccination specific for, 2810
B cell, 275
Plasmodium gallinaceum gametes, monoclonal antibodies against, malaria blockade, 2557
QA-1 encoded, definition, cytotoxic T lymphocyte clones, 2147
selection, class I restriction elements, influenza and, 1635
serologic, HLA-A2-specific, 2935
serum thyroglobulin, autoimmune thyroiditis, 1252
stage- and species-specific, *Leishmania tropica* monoclonal antibodies, 1987
T cell-specific, monoclonal antibodies recognizing, blocking of suppressor T cells and, 1646
tobacco mosaic virus protein, antibody response, 2875
variation, p53 transformation-related protein, 329
Dexamethasone, serosal mast cell biochemistry, modulation by, 934
Dextran
anti-α1→3, response, monoclonal anti-idiotype antibodies, 1375
IgA response, lymphokine activation, 2210
Diabetes, lymphocyte proliferative response, kinetic and cellular aspects, 701
Differentiation antigen
B cell, DR-related, 2458
complex, recognition by monoclonal antibody, 334
T cell, monoclonal antibodies against, macrophage chemiluminescence induced by, 2500
Differentiation factor
B cell
B cell line stimulated by, phospholipid methylation, 1961
interleukin 1 and, WEHI-3 cell line, 1289
T cell-derived lymphokines containing, γ-specific mRNA and, 3049
Dinitrofluorobenzene
contact allergy, desensitization, 2682
contact hypersensitivity reactions to, IgE-mediated, 1096
Dinitrophenyl, fine specificities to, IgG Gar V_L region and, 1871
DNA
gene transfer mediated by, HLA-A2 and HLA-B7 antigen expression, 2032
Lyb-5$^-$ B cells synthesizing, insolubilized anti-Ig antibodies and, 2107
Dorsal lateral plate, mesoderm, hemopoietic cell ontogeny, 2262
DR antigen
F(ab')$_2$ and IgG antibodies to, 725
lymphoproliferation restricted by, blocking with monoclonal antibodies, 2735
DR-related antigen, differentiation, B cell, 2458

Effector cell
graft rejection mediated by, characterization, 92
Ly-2$^+$, cytotoxicity for syngeneic tumor cells, 1017
Ly-23, T cell activation of, antibody suppression, 2154
lymphoproliferation blocking, monoclonal antibodies, 2734
macrophage activation, schistosomiasis and, 948
macrophage as, protective immunity, schistosomiasis, 1481
monocyte subsets as, antibody-dependent cellular cytotoxicity and, 1780
mononuclear, nonoxidative mechanism of natural killer cytotoxicity, 1784
suppressor, immunoregulatory T lymphocytes, viral infection and, 1167
Elutriation, counterflow centrifugal, leukemia cells separated by, histamine release, 911
Encephalomyelitis
experimental allergic
B cell determinant of myelin basic protein, 275
macrophage-myelin basic protein interaction in, 1263
response to, 4
T lymphocyte subsets, 2805
experimental autoimmune, determinant-specific vaccination against, 2810
Endocytosis
IgE oligomers, effect of receptor turnover, 388
macrophage receptor-mediated, lymphokines modulating, 2368
Endothelial cell
antigen presentation by, Ia-positive cells, 666
platelet-activating factor, release from, 2397
pulmonary, platelet-activating factor and antibody-mediated pneumonitis, 1802
Endothelium, lymph node, lymphocyte recognition, 1368
Enzyme
kallikrein-like, glycosylation-enhancing factor, 1954
serine, cell-associated arginine-specific, B cell activation, 2494
Eosinophil
effector function enhancement, *Schistosoma mansoni* proteases and, 464
granule, distinctive cationic proteins, 2977
Epidermal cell, thymocyte-activating factor derived from, chemotactic activity, 816
Epinephrine, lymphocyte subset changes induced by, peripheral blood, 1178
Epithelial antigen, sensitization to, chronic mucosal inflammatory disease, 2796
Epithelial cell
mammary, binding of monoclonal antibodies to, 508
sensitization to antigens, chronic mucosal inflammatory disease, 2796
Epitope
antigenic, lymphocyte function-associated antigen-1, 1182
polyvalent, effect on idiotype suppression, 13
T-200, functionally distinct, blockade of natural killer lysis by, 1742
T cell surface protein Tp50, identification and functional characterization, 180
Epstein Barr virus, *see* Virus
Erythrocyte
altered, macrophage tumoricidal activity inhibition, 2117
C2 and C3 convertase formation and regulation, surface modulation of classical pathway activation, 403
glycophorin A of, monoclonal antibodies against, 864
monoclonal antibodies against, *Plasmodium falciparum* malaria, 2000
monoclonal antibody against, antigen regulation of B cell chronic lymphocytic leukemia, 2046
paroxysmal nocturnal hemoglobinuria, binding of factors B and H to C3b, 2484
Escherichia coli
0111B4, complement-mediated killing, 2563
mutants of, use as lymphocyte markers, 1189
Estrogen, receptors, restriction, OKT8-positive cells, 2767
Excretion, secretion and, *Giardia lamblia*, 2004
Eye
alloantigen inoculation, suppression, delayed-type hypersensitivity, 2670
anterior chamber, trinitrophenyl, immune deviation associated with, contrasuppression, 2746

Factor B, binding to C3b, paroxysmal nocturnal hemoglobinuria erythrocytes, 2484
Factor H, binding to C3b, paroxysmal nocturnal hemoglobinuria erythrocytes, 2484
Fatty acid, free, inhibition of mitogen-induced lymphocyte transformation, 1011
Fc
immunoglobulin carrier, hapten density and, B cell tolerance, 2204
receptor, IgE and IgG, T cells bearing, 2772
Feline leukemia virus, *see* Virus
Fetus
anti-self suppressor cells, liver, 45
B lymphocyte precursor, phenotypic and functional characterization, 572
hematopoietic ontogeny, analysis with monoclonal antibodies, 232
interleukin 2-responsive cells, ontogeny, thymus, 533
Fibroblast, mast cell granule degradation by, 1420
Fibroma virus, *see* Virus
Fibronectin
binding, C1q, 1400
IgA elaboration, mammary cell cultures
Ficoll, trinitrophenyl and, antibody responses to, 633
Filaria, IgE specific for, characterization, 1516
Fine specificity
anti-flavin and anti-dinitrophenyl, IgG Gar V_L region and, 1871
insulin-specific T cell hybridomas, tertiary conformation, 2868
isotype heterogeneity and, anti-arsonate antibodies, 1889
Flavin, fine specificities to, IgG Gar V_L region and, 1871
Flow microfluorometry
disseminated histoplasmosis and, 984
Lyt-2 phenotype and cell cycle status analyzed by, thymus organ cultures, 1085
Follicle, lymph node, immune complex transport to, 1714

Gangliotriaosylceramide, asialo GM$_2$, Hodgkin's disease and, 1591
Gelonin, antibody and, hybrid, target cell killing, 3091
Gene
allotype-linked
antibody responses, tobacco mosaic virus protein, 2875

anti-phosphorylcholine response phenotype, 1570
A region, T cell-specific determinants controlled by, 1646
C and V, expression in B cells, 1629
class II products, functional characteristics, H-2 haplotype, 2432
DNA-mediated transfer, HLA-A2 and HLA-B7 antigen expression, 2032
H-2D region-associated antigens, H-2 haplotypes, 2440
heavy chain- and major histocompatibility complex-linked, immunoglobulin-recognizing T cells and, 103
histocompatibility, class II, recombination and mutation, 3052
Ia Aβ chain, polymorphism surrounding, 2025
immune response, lactate dehydrogenase B and mineral oil-induced plasmacytoma-173, separation, 2919
Ity
expression, hepatic and splenic macrophages, 3014
expression, peritoneal and splenic macrophages, 3006
product, latent IgG allotypes, 1860
retroviral envelope glycoprotein, lymphocyte activation and, 3036
Salmonella susceptibility, control, 2613
xid, studies, 2789
X-linked immune deficiency, Y chromosome-related disease and, 1257
Genetics, scrapie and Creutzfeldt-Jakob disease, 491
Genotype
B cell, interaction preference with T cells and, 9
QA-1, encoded determinants, definition, cytotoxic T lymphocyte clones, 2147
Germinal center, B memory cells, generation, 2254
Giardia lamblia, excretory-secretory products of, 2004
γ-Globulin, tolerance, NZB cells preventing, 1121
Glomerulonephritis
autoantibody development and, B cell hyperactivity, 2232
immune complex, auto-anti-idiotypes in, 2781
Glucocorticoid, effects on monocyte Fc receptors, hemolytic anemia and, 1240
Glycophorin A, monoclonal antibodies against, erythrocyte, 864
Glycoprotein
feline leukemia virus envelope gp70, monoclonal antibodies to subgroups B and C, 3042
gp130, melanoma cells, 1595
major histocompatibility complex antigens, schistosome, 962
retroviral envelope, expression, lymphocyte activation and, 3036
surface, T4 and T8, genetic restriction to, 186
T-200, monoclonal antibody to, natural killer cytolytic "trigger," 1149
Glycosphingolipid, marker, asialo GM_2, Hodgkin's disease and, 1591
Glycosylation
factor enhancing, kallikrein-like enzyme, 1954
sex-limited protein, variation in, 1405
T cell antigen Leu-4, 1876
Gonadotropin, human chorionic, monoclonal antibodies to, circular antibody-antigen complex and, 1900
Graft-vs-host disease
acute cutaneous, keratinocyte synthesis of Ia antigen, 2741
immunosuppression associated with, cytotoxic T lymphocytes in host spleen and, 1142
prevention, anti-asialo GM_1, 2101
Graft-vs-leukemia activity, T lymphocytes reactive against leukemia, 2050
Granulocyte
cytotoxic function, activation, colony-stimulating factor, 2983
histaminase release, induction by particle-bound C3 cleavage products, 439
peripheral blood, mixed lymphocyte reaction stimulatory ability of mature myelomonocytic cells, 736
surface antigen, identification by monoclonal antibodies, 1882
Granulocyte-macrophage, progenitor cells, γ, α and β interferon comparison, 1300
Granuloma
liver
angiotensins in, *Schistosoma mansoni*, 2529
mast cell density, 959
Granulomatous disease, mononuclear effector cells from, nonoxidative mechanism of natural killer cytotoxicity, 1784
Growth factor
B cell
biochemical and physicochemical characterization, 1838
interleukin 1 and, WEHI-3 cell line, 1289
mast cell, homogeneous interleukin 3, 282
mesangial, macrophage interleukin 1, 2830
T cell, concanavalin A-induced reactivity, Lyt-2-positive T cell precursors and, 19
Guanosine-3′:5′ cyclic monophosphate, macrophage susceptibility to *Trypanosoma cruzi*, modulatory effect, 3028

H-2 antigen
class I, neonatal tolerance to, 1676
class I and class II, neonatal tolerance-inducing capacities, 1670
enhanced expression, γ-interferon-induced, 788
haplotype
H-2D region gene products, 2440
variant class II molecules, 2432
induction on macrophage cell line, immune interferon, 315
restricted and unrestircted bystander responses, B cell, 581
Haplotype
H-2
H-2D region gene products, 2440
variant class II molecules, 2432
Hapten
B lymphocytes specific for, cloning efficiencies, 554
colony-forming B cells specific for, subpopulation delineation, 587
cytotoxic T cell tolerance induced by, clonal deletion and suppression, 2661
cytotoxic T lymphocytes specific for
responses, Ia determinant recognition and, 1650
unresponsiveness in, 1663
delayed-type hypersensitivity specific for, (4-hydroxy-3-nitrophenyl)acetyl-coupled proteins and, 70
density, immunoglobulins, B cell tolerance and, 2204
intratracheal administration, allergic contact dermatitis induced by, 1748
T cell immunity specific for, viral infection effects on, 30
T cell response specific for, hyporesponsiveness induction, 2184
H-2D region
gene products, H-2 haplotypes, 2440
self class I histocompatibility antigen in, interleukin 2-secreting T cell hybridoma responding to, 1656
Heavy chain, genes linked to, immunoglobulin-recognizing T cells and, 103
Helper cell
immunoregulatory T lymphocytes, viral infection and, 1167
interleukin 2-producing, activation, 520
OKT4-defined T lymphocyte subset, newborn, 1765
Hemagglutinin, virus, cross-reacting antibodies, 1546
Hemoglobinuria, paroxysmal nocturnal, erythrocytes, binding of factors B and H to C3b, 2484
Hemopoietic cell, ontogeny, dual embryonic origin, 2262
Heparin
mast cell granule-associated suppressor factor, lymphocyte blastogenesis and, 1942
matrix of mast cell granules, degradation by fibroblasts, 1420
Hepatitis, virus-induced, natural killer cell depletion and, 1531
Heredity, acquired immunologic hyporesponsiveness, maternal influence, 1115
Herpes labialis, spontaneous interferon production, peripheral blood mononuclear leukocytes, 2826
Herpes simplex virus, *see* Virus
Histaminase, release, induction by particle-bound C3 cleavage products, 439
Histamine
cells containing, mucosal mast cells, 915
cell-stimulating factor producing, homogeneous interleukin 3, 282
receptor, mononuclear cells bearing, 1854
release
basophilic leukemia cells, cell cycle-associated changes, 911
enhanced passive sensitization for, 1949
Histocompatibility complex
major
antigen expression in L cells, 2032
antigens, 2939
antigens, trophoblast cells, pregnancy, 2348
class I antigen, interleukin 2-secreting T cell hybridoma responding to, 1656
class I antigen, thymic differentiation markers, 351
class I restriction elements, determinant selection by, 1635
class II antigen reactivity, 2178
class II, cytotoxic T lymphocyte clones specific for, 678
genes linked to, immunoglobulin-recognizing T cells and, 103
genes, recombination and mutation, 3052
H-2, *H-2D* region gene products, 2440
H-2, variant class II molecules, 2432
hyporesponsiveness induction, hapten-specific T cell response, 2184
restriction specificity, antigen-specific T cell lines, 1641
schistosome antigens, 962
T cell lines and clones restricted by, interferon and, 1049
minor, cytolytic T cells specific for, 2135
Histoplasmosis, disseminated, immunoregulation in, 984
HLA
class I- and class II-specific monoclonal antibodies, lymphoproliferation blocking with, 2735
class II antigen, T cell recognition of, T4 molecule involvement, 152
rapid turnover, quiescent lymphocytes, 341
HLA-A2 antigen
HLA-B7 antigen and, DNA-mediated gene transfer, 2032
immunoselected mutant 8.6.1, structural analysis, 2935
structure, 856
HLA-B7 antigen, HLA-A2 antigen and, DNA-mediated gene transfer, 2032
HLA-DR antigen, DR4 and DR2, anti-idiotypic antibodies to, 2890
HNK-1$^+$ cell, activated, interleukin 2 receptor expression by, 1822
Hodgkin's disease, cell lines, asialo GM_2 on, 1591
Homologue, Thy-1.2, cytotoxic lymphocytes positive and negative for, 622
Host, genetically controlled resistance, *Mycobacterium bovis*, 1966
Host-vs-graft disease, allogenic, B cell function, 2623
Human chorionic gonadotropin, *see* Gonadotropin
H-Y antigen, frequency of responsiveness, 325
Hybrid
antibody-ricin A chain or antibody-gelonin, target cell killing, 3091
somatic cell, sensitivity to natural killer and natural cytotoxic cell lysis, 1154
Hybridoma
anti-bovine insulin, idiotypes, 2882
autoantibody synthesis, vaccinia infection and, 1546
B cell
B cell surface antigens and, 98
common variable immunodeficiency, 2273
cytotoxic T lymphocyte, bifunctional, 50
development, optimal human cell lines for, 1201
immunoglobulin class switch variants from, isolation by sequential sublining, 877
macrophage-activating factor, polyinosinic-polycytidylic acid and, 311
monoclonal antibodies reacting with self antigens, secretion, 2267
T cell
antigen-specific suppressor factors, 2643
coordinate production of lymphokines by, 794
insulin-specific, fine specificity, 2868
lymphocyte maturation factor and, 1816
macrophage-activating factor produced by, 826
polyclonal T cell activator and, 543
production of IgA binding factor by, 303
self H-2D-responsive, 1656
Hydrogen peroxide, production, lymphokine-stimulated monocyte, 2853
Hydrogen peroxide-potentiating factor, hydrogen

Hydrogen peroxide-potentiating factor—*continued*
peroxide production, lymphokine-stimulated monocyte, 2853
(4-Hydroxy-3-nitrophenyl)acetyl, proteins coupled to, absence of hapten-specific delayed-type hypersensitivity to, 70
Hyperactivity, autoimmunity and, B cell, 2232
Hyperreactivity, respiratory responses, leukotrienes and biogenic amines, 434
Hypersensitivity
contact, IgE-mediated reactions to dinitrofluorobenzene, 1096
cutaneous basophil, antibody-mediated, 2674
delayed-type
defective elicitation, mast cell deficiency, 2687
hapten-specific, (4-hydroxy-3-nitrophenyl)-acetyl and, 70
helper T cells, induction and regulation, 77
humoral mode *vs*, T cell effects, 1103
intracamerally induced suppression, 2670
reaction sites, macrophage chemotactic factors from, 2989
granulomatous, modulation, 959
Hyporesponsiveness
acquired immunologic, maternal influence, 115
preferential induction, D-end, major histocompatibility complex, T cell response, 2184

Ia antigen
Aβ chain, polymorphism surrounding, 2025
B lymphocyte receptor, interferon-α/β induction, 1895
enhanced expression, γ-interferon-induced, 788
Ia.3,5, tryptic peptide disparity between, 845
induction on macrophage cell line, immune interferon, 315
invariant chain, oligosaccharides of, 352
presentation, induction, P388D1 cells, 2814
restricted presentation, J774.2 cells, 674
splenocyte and thymocyte, comparison, 1386
synthesis by keratinocytes, graft-*vs*-host disease, 2741
Tac antigen and, *in vivo* stimulated T cells, 731
T cells reactive with, inhibition of proliferation, 1056
Idiotope
antibodies against, hybridomas secreting, isolation of isotype variants, 877
recurrent, syngeneic anti-idiotypes against monoclonal anti-HLA-DR antibodies, 1339
site-related, anti-idiotype-induced immunity against trypanosomes, 1511
Idiotype
antibodies against
autoimmune tubulointerstitial nephritis and, 1268
HLA-DR4 and DR2, 2890
immune complex glomerulonephritis, 2781
trypanosomiasis and, 1511
cross-reactive
anti-*p*-azophenylarsonate antibody and, 423
monoclonal antibodies to thyroglobulin, 2452
determinants
cross-reacting, polyclonal immunoglobulin, 3001
tumor immunotherapy, 1600
monoclonal antibodies, bovine insulin, 2882
monoclonal antibodies against, anti-α1→3 dextran response, 1375
myeloma suppression specific for, accessory cell role, 1728
reovirus receptor, monoclonal anti-idiotypic antibody identifying, 2533
sera against, monoclonal anti-HLA-DR antibodies and, 1339
suppression, polyvalent epitope effects on, 13
urinary light chain, antibodies against, neoplastic B lymphocytes, 3058
viral receptor, monoclonal anti-idiotype antibody blocking viral binding, 2539
VK_1^{BAC} light chain, association with serum IgG3, 1326
Idiotype-isotype expression, asymmetry, response to phosphocholine, 2468
I-J subregion, expression, T cell, enhancement by proteolysis, 1380
Immune capacity, bursectomy and incubation, cell proliferation and immunoglobulin secretion, 120
Immune complex
altered erythrocytes and, macrophage tumoricidal activity inhibition, 2117
cellular cytotoxicity dependent on, mechanisms of macrophage cytotoxicity, 1438
disease, neonatal induction of transplantation tolerance and, 251
glomerulonephritis, auto-anti-idiotypes in, 2781
IgG, abnormal binding to hepatic nonparenchymal cells, 2784
lymphocyte surface-bound, interaction with neutrophils, 207
transport to lymph node follicles, 1714
Immune deficiency, X-linked, Y chromosome-related disease, 1257
Immune function, cell-mediated, leukocyte cell surface antigen and, 2913
Immune regulation, monoclonal antibodies, failure to enhance skin allografts, 86
Immune response
allocantigens, regulation, 1065
antitumor, suppression, continuous T cell line and, 514
Epstein Barr virus-induced, systemic lupus erythematosus, 1797
gene separation, lactate dehydrogenase B and mineral oil-induced plasmacytoma-173, 2919
humoral
syphilis, 1973
viral proteins, cytomegalovirus, 3032
insulin, lymphocyte proliferative response, 701
lymphokine soluble suppressor, purification, 2848
secretory antibody production and, Peyer's patch cells primed for, 2616
suppression, synthetic C3a peptides, 2258
systemic, enterically induced regulation, 2651, 2656
T cell-mediated, viral infection effects on, 30
Immune system
anti-δ suppression, effect on B cell subpopulations, neonate, 593
polyclonal activation, anti-δ activation, 2226
Immunity
anti-idiotype-induced, trypanosomes and, 1511
arthritis, collagen injection, 2995
cell-mediated, Leishmanial antigen-specific T cells and, 1496
intraocular concomitant, metastases and secondary tumor challenge, 2587
protective
macrophage activation, schistosomiasis and, 948
macrophages as effector cells of, schistosomiasis, 1481
mast cells and IgE antibodies against *Schistosoma mansoni*, 1460
Pseudomonas aeruginosa, ribosomal vaccine, 1
Immunization
parenteral, cell-mediated suppression of mucosal IgA response, 115
Streptococcus mutans, serology and tissue lesions, 3021
Immunoadsorbent, interleukin 1 purification, 1834
Immunochemistry, lymphocyte function-associated antigen-1, 1182
Immunodeficiency
common variable, B cell hybridomas from, 2273
severe combined, natural killer cell function, 2332
X-linked
IgA responses, 2616
lymphokine-induced responses to trinitrophenyl-Ficoll, 1698
Immunogenicity
tolerogenicity and, T-independent antigens, 2196
tumor antigen, liposomes and, 485
Immunoglobulin
antibody against, insolubilized, Lyb-5$^-$ B cells stimulated with, 2107
antisera, T lymphoma cell surface molecule recognition, virus gp70 and, 1576
C and V gene expression, frequency analysis, B cells, 1629
class switch variants, isolation by sequential sublining, 877
Fab determinants, T cell tumor product, cross-reaction with, 1582
F(ab')$_2$ fragments, tumor immunotherapy, 1600
haptenated, B cell tolerance induced by, 2204
IgA
anti-dextran response, lymphokine activation, 2210
binding factor production, T cell hybridoma, 303
deficiency and nephropathy, Fcα receptor in, 1246
elaboration in mammary cell cultures, 869
responses, cell-mediated suppression of, 115
responses, X-linked immunodeficiency disease, 2616
IgD, antibody to, immune defective B cell activation, 2226
IgE
antibodies, immunity against *Schistosoma mansoni*, 1460
binding to basophilic leukemia cells, fate of, 388
class-specific suppressor T cells and factors, 2750
contact hypersensitivity mediated by, 1096
dissociation from receptors on basophils, 1949
factors binding, modulation, 1090, 1954
filariasis, 1516
formation, peripheral blood mononuclear cells, 3001
leukotriene generation dependent on, mastocytoma cells, 906
mast cell sensitization, platelet-activating factor release, 2958
IgE and IgG, Fc receptors, T cells bearing, 2772
IgG
abnormal immune complex binding to hepatic nonparenchymal cells, 2784
antibodies, DR antigens and, 725
B cell differentiation factors for, γ-specific mRNA, 3049
C5b-9 *Escherichia coli* 0111B4 bactericidal efficiency and, 2571
cross-reactive anti-idiotypic antibodies, rheumatoid factors, 719
Gar V_L region, modeled structure, 1871
induction of granulocyte histaminase release by, 439
latent allotypes, 1860
monocyte Fc receptors in hemolytic anemia, 1240
oligoclonal cerebrospinal fluid, multiple sclerosis, 2328
soluble aggregates, C1 activation by, 1924
subclass responses to lipopolysaccharide, 6
suppression, *Trypanosoma cruzi* and, 1978
T cell factor-mediated suppression, 298
IgG3, monoclonal antibodies to streptococcal group A carbohydrate, 1326
IgG1, IgG2a, and IgG2b, fragmentation, 2895
IgG and F(ab')$_2$, *Escherichia coli* killing mediated by, 2563
IgG and IgM, antibodies, *Toxoplasma gondii* recognition by, 977
IgM, cell surface, tumor immunotherapy and, 1600
IgM and all IgG isotypes, monoclonal antibodies, cell-mediated tumor target lysis, 1028
IgM and IgD, monoclonal antibodies against, B cell differentiation and, 1306
isotype diversity, generation, B lineage cell differentiation, 1688
secretion, bursectomy and incubation, 120
T cells recognized by, influence of heavy chain and major histocompatibility complex, 103
Immunohistology, large granular lymphocyte, 132
Immunoperoxidase, localization, large granular lymphocytes, 132
Immunoregulation
B cell responses to thymic-independent antigens, 1131
disseminated histoplasmosis and, 984
trinitrophenyl-specific molecules, characterization, 2859
Immunoselection, antibody-toxin hybrid molecules, target cell killing, 3091
Immunosuppression
general, lack of, visceral *Leishmaniasis tropica* infection and, 1492
graft-*vs*-host reaction-associated, cytotoxic T lymphocytes in host spleen and, 1142
nonspecific, tumor virus-induced, 2595
Immunotherapy, B cell tumor, anti-idiotypes and, 1600
Incubation, bursectomy and, immune capacity, 120
Inducer cell, suppressor, immunoregulatory T lymphocytes, viral infection and, 1167
Infection, *see* specific site and type
Influenza, *see* Virus
Instructor cell, Leu-3a$^+$, monocyte procoagulant activity and, 749
Insulin
bovine, idiotypes on monoclonal antibodies, 2882
immune response to, lymphocyte proliferative response, 701

receptor, B cell, T cell cooperation for genesis of, 644
T cell hybridoma specific for, fine specificity, 2867
Interferon
immune
Ia and H-2 antigen induction on macrophage cell line, 315
macrophage-activating factor-like activity, 2821
production, autoimmunity and, 265
interleukin 2, colony-stimulating factor, and, production, large granular lymphocytes, 2379
leukocyte
suppressor T cell activation, 2301
two types, B cell proliferation by, 238
natural killer cell cytotoxicity and, persistent viral infection, 991
production and proliferation, antigen-specific proliferative T cell clones, 1049
spontaneous production, herpes labialis, 2827
virus-infected cells treated with, natural killer lysis, 783
virus-specific natural killer activity and, 1849
α-Interferon
β-interferon and, colony-stimulating factor enhanced by, 2374
γ- and β-interferon, multipotential, erythroid, and granulocyte-macrophage progenitor cells, 1300
α/β-Interferon, induction, B lymphocyte receptor and, 1895
β-Interferon
α-interferon and, colony-stimulating factor enhanced by, 2374
γ- and α-interferon, multipotential, erythroid, and granulocyte-macrophage progenitor cells, 1300
γ-Interferon
antigen presentation, mediation by, P388D1 cells, 2814
coordinate production by T cell hybridoma, 794
hybridoma-derived macrophage-activating factor resembling, 826
Ia and H-2 antigen induction by, B lymphoid, macrophage, and myeloid cell lines, 788
induction, mycoplasma mitogen and phytohemagglutinin, 2392
α- and β-interferon, multipotential, erythroid, and granulocyte-macrophage progenitor cells, 1300
lymphokine, *Chlamydia psittaci* inhibition, 2542
production, interleukin 2-induced, 288
T cell lines producing, 1611
Interleukin, inducible secretion, cytotoxic T lymphocyte hybridomas capable of, 50
Interleukin 1
antibodies against, immunoadsorbent for purification, 1834
B cell activation and proliferation, effects on, 801
B cell growth and differentiation factor and, WEHI-3 cell line, 1289
detection, biologic assay, 1280
macrophage, mesangial cell proliferation and, 2830
requirement for, antigen presentation by monocytes, 1160
12-O-tetradecanoylphorbol-13-acetate and, thymocyte differentiation induced by, 201
Interleukin 2
cells responsive to, ontogeny, fetal thymus, 533
colony-stimulating factors and, coordinate synthesis in T cell lymphoma, 293
cyclophosphamide-resistant cytotoxic precursors, expansion by, 806
deficiency, Leishmaniasis donovani, 1487
helper cells producing, activation, 520
interferon, colony-stimulating factor, and, production, large granular lymphocytes, 2379
γ-interferon production induced by, participation of macrophages and natural killer-like cells, 288
lectin-stimulated release, kinetics, 1274
lymphokine distinct from, B cell growth factor, 1838
marrow transplant recipients and, 1771
monoclonal antibodies to, production and characterization, 1808
natural killer-like cytotoxic cell lines, growth requirements, 2386
production
action and, interference by ouabain, 1433
inhibition, bone marrow transplantation and, 1205
inhibitors from tumor cells, 2837
mitogen-stimulated T cell subsets, 2864
OKT8 antibody regulating, 2356
thymocyte differentiation, interleukin 1- or phorbol ester-induced, 201
purification, 810
receptor
blockade by anti-Tac antibody, 690
expression by HNK-1$^+$ granular lymphocytes, 1822
supernatants containing, activation of nonspecific killer cells by, 1827
T cell hybridoma secreting, self H-2D-responsive, 1656
Thy-1$^-$ cells receptive to, natural killer cells during lymphatic regeneration, 658
Interleukin 3, homogeneous, biologic properties, 282
Intestine
IgA response, cell-mediated suppression of, 115
systemic immune responses, enterically induced regulation, 2651, 2656
vasoactive polypeptide, receptors on peripheral blood lymphocytes, 1173
Invariant chain, Ia-associated, oligosaccharides of, 352
Ionophore, leukotriene generation induced by, mastocytoma cells, 906
Irradiation
total lymphoid
B and T cell subset modulation, 1683
fractionated, suppressor cell characterization, 1108
Isotype
B cell, switching, 1693
expression, T cell regulation of, 2170
Fc receptors for, T cell hybridomas coexpressing, 303
heterogeneity, anti-arsonate antibodies, 1869
IgG, monoclonal antibodies, cell-mediated tumor target lysis, 1028
variant, isolation by sequential sublining, 877

Kallikrein, enzyme similar to, glycosylation-enhancing factor, 1954
Keratinocyte, Ia antigen synthesis by, graft-*vs*-host disease, 2741
Kidney cell, rabies virus vaccine, antigen-specific antibody response, 1234
Killer cell
activated, natural killer cells and, teratocarcinoma targets distinguishing, 1007
autoreactive, generation, 2128
characterization, single cell level, 2340
natural killer cells and, expression of antigen recognized by antibody OKT8, 223
nonspecific, activation by interleukin 2-containing supernatants, 1827

Lactate dehydrogenase B
mineral oil-induced plasmacytoma-173 and, immune response gene separation, 2919
response to, suppressor and helper T cell interaction, 628
Langerhans cell, anti-Leu-3/T4 antibodies reacting with, 212
Late phase reactions, cutaneous, anti-neutrophil antibody-induced neutropenia, effect on, 929
L cell, HLA-A2 and HLA-B7 antigens in, 2032
Leishmania donovani
amastigotes, survival in monocytes, 1994
antigens, recognition by T cells, 1496
Leishmania mexicana, monoclonal antibodies to, *in vivo* protection, 1616
Leishmaniasis, chronic cutaneous, survival in activated macrophages, 966
Leishmaniasis donovani, interleukin 2 deficiency in, depressed spleen cell responses to phytohemagglutinin, 1487
Leishmania tropica
monoclonal antibodies specific for, stage- and species-specific determinants, 1987
visceral infection, lack of general immunosuppression during, 1492
Letters to the Editor, 2094, 2606
Leu-2$^+$ cell, phenotypically distinct subset, T cell proliferation, suppression by, 2757
L-Leucine methyl ester, accessory cell sensitivity to, phenotype, 2282
Leukemia
acute, surface antigen T305 found in cells, 762
alloimmunization-induced T lymphocytes reactive with, graft-*vs*-leukemia activity, 2050
antigen associated with, characterization, 2038
basophilic cells, cell cycle-associated changes in histamine release from, 911
chronic and acute lymphocytic, monoclonal antibody detecting 39,000 m.w. molecule, 3064
chronic lymphocytic, B cell, antigen regulation, 2046
thymus, antigen, structural identity of homologues, 1344
virus, *see* Virus
Leukemia cell, basophilic, fate of IgE bound to, 388
Leukocyte
antibodies against, Fc receptor blockade by, 140
antibody-dependent killing of *Cryptococcus neoformans*, 1455
cell surface antigen, immune function and, 2913
complement, C5 in lymphocyte stimulation, 886
interferon
suppressor T cell activation, 2301
two types, B cell proliferation by, 238
mixed, anti-tumor cytotoxic T lymphocyte activation and, 1017
mononuclear, peroxidase-positive, dendritic reticulum cell precursors, 2719
motility and chemotaxis parameters, measurement, 940
peripheral blood, spontaneous interferon production, herpes labialis, 2827
polymorphonuclear, cytotoxic, induction by concanavalin A supernatant, 2508
pulmonary endothelial cells and, platelet-activating factor and antibody-mediated pneumonitis, 1802
recombinant interferon, therapy, natural killer activity after, 503
Leukotriene
biogenic amines and, respiratory responses to, 434
IgE-dependent and ionophore-induced generation, mastocytoma cells, 906
slow-reacting substance of anaphylaxis, specific radioimmunoassay development, 429
Leukotriene B_4, T lymphocyte function suppression by, 551
Ligand, detergent-insoluble membrane proteins and, 1917
Light chain
αIIb, association with IgMκ autoantibodies, 1322
urinary, idiotypes, antibodies against, neoplastic B lymphocytes, 3058
λVI, Bence Jones protein SUT, region sequence, 2490
$V\kappa_1^{GAC}$, association with serum IgG3, 1326
κ-Light chain, different allotypes, splenic mRNA analyses, 1000
Lineage cell, B lymphocyte, regulatory disorders, neonate, 2219
Lipid, modulating agents, major histocompatibility complex and Thy-1.2 expression modification by, 1356
Lipid bodies, arachidonate metabolism, macrophage and mast cell, 2965
Lipomodulin, phospholipase inhibitory protein, inhibition of natural killer and antibody-dependent cellular cytotoxicity activities by, 662
Lipopolysaccharide
bacterial response to, instructor cell for procoagulant monocyte response to, 749
high-density lipoprotein and, binding, control by acute phase proteins, 1913
IgG subclass response modulation, bacterial membrane components and, 6
pathogenicity of *Treponema hyodysenteriae* and, 997
responsiveness of lymphocytes, microinjection of signal-transmitting cytoplasmic factors, 1294
Lipoprotein, high-density, lipopolysaccharide binding to, acute phase proteins and, 1913
Liposome
antibody-bearing, T-independent antigen mobility on, 2924
membrane-like immunogen, tumor antigen and, 485
polyinosinic-polycytidylic acid encapsulated in, hybridoma macrophage-activating factor and, 311
Lipoxygenase, antagonists, natural killer inhibition by, 2953
Listeriosis, T cell deficiency, cortisone and cyclosporin A effects, 450
Liver
anti-self suppressor cells, fetal, 45
L-arginase, lymphocyte-specific liver-derived in-

Liver—*continued*
hibitory protein, 2427
B lineage cells, differentiation, immunoglobulin isotype diversity, 1693
granuloma
angiotensins in, *Schistosoma mansoni*, 2529
mast cell density, 959
macrophages, *Ity* gene expression, 3014
nonparenchymal cells, abnormal immune complex binding to, 2784
L3T4 antigen, class II major histocompatibility complex antigen and, reactivity, 2178
Luminol, neutrophil chemiluminescence dependent on, inhibition by polyanions, 2515
Lung
antibody-mediated injury, platelet-activating factor and, 1802
cancer, non-small cell, p31 on, 497
hapten administration, allergic contact dermatitis induced by, 1748
natural killer cells, phenotype, influenza infection and, 2698
Lupus erythematosus
systemic
abnormal suppressor cell subsets, 753
anti-histone antibodies, 269
immune responses, Epstein Barr virus and, 1797
monocyte Fc receptors in, 217
Lymphatic regeneration
alloreactive and self-restricted cytotoxic T lymphocyte precursors during, frequencies, 548
natural killer cell activity during, 659
Lymph node
follicles, immune complex transport to, 1714
fractionation, peanut agglutinin receptors, B cell memory transfer, 2254
high epithelium, lymphocyte recognition of, 1368
Lymphocyte
see also specific type and site
activation
endogenous retroviral gene expression and, 3036
trypanosomal surface coat variant antigen causing, 1983
adhesion molecules, lymph node high epithelium recognition by, 1368
allogeneic interaction, thymus-dependent and -independent antigens, 2246
B cell hybridomas from, common variable immunodeficiency, 2273
blastogenesis, mast cell granule effects on, 1942
blood, fine specificity of antibody response to influenza virus, 1229
cell surface, actin, 370
chemoattractant lymphokines, production, histamine and, 1854
cord blood
function in antibody production, 1222
T cell lymphoma virus-infected, antigen expression, 2021
cytoskeleton, rosette receptor and, 1126
Fcα receptor, IgA deficiency and nephropathy, 1246
granular, HNK-1$^+$, interleukin 2 receptor expression by, 1822
large granular
immunoperoxidase localization of, 132
interleukin 2, interferon, and colony-stimulating factor production, 2379
tumor cell clearance, anti-asialo GM$_1$ and, 1024
lipopolysaccharide responsiveness, microinjection of signal-transmitting cytoplasmic factors, 1294
liver-derived inhibitory protein specific for, arginase activity, 2427
markers, *Escherichia coli* mutants as, 1189
maturation factor, T cell hybridoma effects on, 1816
membrane protein, detergent-insoluble lymphocyte cytoskeletal matrix and, 1917
mitogen-induced proliferation, inhibition by ouabain, 1433
mitogen-induced transformation, inhibition, free fatty acids and, 1011
mixed
immune response, T cells generated in, 1065
reactivity, blocking, 2323
non-B, unique Fc$_\gamma$ of, 378
nonspecific cytotoxic, Thy-1.2 homologue-positive and -negative, induction, 622
peripheral
surface marker expression on, aging and, 191
thymectomy effects, myasthenia gravis, 773
peripheral blood
activation inhibition by anti-Tac antibody, 690
nonadherent, vasoactive intestinal polypeptide receptors on, 1173
oligoclonal cerebrospinal fluid IgG, multiple sclerosis, 2328
rabies-specific antibody production, 1234
phospholipid vesicles and, binding of cyclosporine by, 712
primed lymphocyte test, nonspecific proliferative responses in, 165
proliferation and natural killer activity, induction by mature myelomonocytic cells, 736
proliferative response, insulin and, 701
quiescent, turnover of HLA protein in, 340
resting, transcription inhibition, deoxyadenosine, 2761
rheumatoid arthritis, impaired regulation of Epstein Barr virus transformation in, 768
stimulation, possible role of C5 in, 886
subset changes, epinephrine-induced, peripheral blood, 1178
suppression of responsiveness, tumor-derived cells and, 3065
surface, C-reactive protein antigenicity on, 2930
surface-bound immune complexes, interaction with neutrophils, 207
unprimed, change from cell-mediated to humoral response, analysis, 1103
virus-specific response, progressive Aleutian disease, 1558
Lymphoid cell, Ia and H-2 antigen induction, γ-interferon-induced, 788
Lymphoid organ, peripheral, T cell renewal rate and expansion in, 2158
Lymphoid tissue, germinal centers, generation of B memory cells, 2254
Lymphokine
anti-trinitrophenyl-Ficoll response, X-linked B lymphocyte defect, 1698
B cell-derived, regulatory function of Thy-1$^-$ cells, 1283
coordinate production of, T cell hybridoma, 794
distinction from interleukin 2, B cell growth factor, 1838
IgA anti-polysaccharide response, activation by, 2210
γ-interferon, *Chlamydia psittaci* inhibition, 2542
interleukin 2, interferon, and colony-stimulating factor, production, large granular lymphocytes, 2379
macrophage activation mediated by, schistosomiasis, 1481
macrophage receptor-mediated endocytosis, modulation by, 2368
production, histamine-induced, 1854
release, monoclonal antibody GK1.5 blocking, 2178
soluble immune response suppressor, purification, 2848
T cell-derived
B cell differentiation factors for IgG, 3049
coordinate regulation, 293
Lymphoma
B cell
known antigen specificity, 2064
processed antigen, 2726
induction, anti-μ, 2069
T cell
interleukin 2 and colony-stimulating factors in, 293
virus, *see* Virus
Lymphomagenesis, antigen-induced, B cell lymphoma with known antigen specificity, 2064
Lymphoproliferation, blocking, monoclonal antibodies, 2735
Lymphoproliferative response, ingested antigen suppression by, 2651
Lysis
cell-mediated, tumor target cytotoxicity using monoclonal antibodies, 1028
modulation, cytotoxic T lymphocyte clones, 2141
natural killer cell
blockade, functionally distinct epitopes of T-200 and, 1742
herpes simplex virus-infected cells, 2011
interferon-treated virus-infected cells, 783
natural killer cell- and natural cytotoxic cell-mediated, sensitivity of somatic cell hybrids, 1154
Lysosomotropic agent, natural killer activity, inhibition by, 125

Macrophage
activation
hybridoma macrophage-activating factor and polyinosinic-polycytidylic acid, synergism between, 311
Leishmania survival in, 966
mycobacteria resistance to killing by, 1452
alveolar, acetylated cytochrome *c* detecting superoxide anion, 2104
antigen-specific activation, schistosomiasis and, 1481
antigen-specific T cell activation dependent on, requirements, 23
antimicrobial activity, suppression by tumor cell product, 384
arachidonate metabolism, lipid bodies, 2965
B cell tolerization by, 2122
binding to tumor cells, 2086
cell line, Ia and H-2 antigen induction on, immune interferon, 315
cell lineage, anti-Leu-3/T4 antibodies reacting with, 212
chemiluminescence, anti-T cell monoclonal antibody-induced, 2500
chemotactic, subpopulation definition, 2989
cytotoxicity, mechanisms, 1438
cytotoxicity mediated by, soluble cytotoxic factor from, 2362
differential binding, thymocyte subsets, 2110
hepatic and splenic, *Ity* gene expression, 3014
Ia and H-2 antigen induction, γ-interferon-induced, 788
independence, defective B cell tolerance induction, 2630
interleukin 1, mesangial cell proliferation and, 2830
interleukin 2 induction of γ-interferon production, participation in, 288
lymphokine γ-interferon, *Chlamydia psittaci* inhibition, 2542
monoclonal antibodies directed against, tumor cytotoxicity and, 1032
myelin basic protein and, interaction, experimental allergic encephalomyelitis, 1263
peritoneal, neonatal resistance to Toxoplasma infection, 1527
peritoneal and splenic, *Ity* gene expression, 3006
peritoneal exudate, T cell activation and, 2714
precursor, colony-stimulating factor, interferon-enhanced responsiveness, 2374
prostaglandins and, natural killer-derived cytotoxic T lymphocytes, activation, 1734
receptor, endocytosis mediated by, 2368
surface C4-positive, complement secretion by, 2420
susceptibility to *Trypanosoma cruzi*, modulation, guanosine-3′:5′ cyclic monophosphate, 3028
Thy-1.2 homologue-positive cells distinct from, vaccinia-induced peritoneal exudate cytotoxicity mediated by, 2545
tumor-associated, mammary tumors, 2074, 2079
tumoricidal activity, inhibiton, immune complexes and altered erythrocytes, 2117
tumoricidal capacity, suppressive activity and, dissociation between, 1707
Macrophage-activating factor
monocyte cytotoxicity and, immune interferon, 2821
production by T cell hybridoma, resemblance to γ-interferon, 826
T cell clones, induction of distinct macrophage functions, 833
Malaria
cerebral, prevention, adoptive transfer of malaria-specific T cells and, 1522
parasite transmission, monoclonal antibodies blocking, 2557
Plasmodium falciparum, monoclonal antibodies to, 2000
Mammary cell
epithelial, binding of monoclonal antibodies to, complexity of antigenic determinant expression, 508
IgA elaboration in, relationship to fibronectin matrix, 889
Mast cell
arachidonate metabolism, lipid bodies, 2965
bone marrow-derived, platelet-activating factor release from, 2958
deficiency, defective elicitation of delayed-type hypersensitivity, 2687
density, T lymphocyte subsets influencing, liver granuloma, 959
granules
biologic activity, 929
degradation by fibroblasts, 1420

effect on lymphocyte blastogenesis, 1942
growth factor, homogeneous interleukin 3, 282
heterogeneity, 1936
IgE antibodies and, immunity against *Schistosoma mansoni*, 1460
mucosal, histamine-containing bone marrow cells, 915
precursor, frequency in normal tissue, 923
serosal, biochemistry modulation, dexamethasone and, 934
Mastocytoma cells, leukotrienes from, IgE-dependent and ionophore-induced generation of, 906
Melanoma, gp130 on, biochemical analysis, 1595
Memory
B cell
development, differential sensitivity to stimulation with thymus-dependent and -independent antigens, 567
germinal center generation of, 2254
Mesangial cell, proliferation, stimulation, interleukin 1, 2829
Mesoderm, dorsal lateral plate, hemopoietic cell ontogeny, 2262
Metastasis
macrophages from
mammary tumors, cytotoxicity, 2079
mammary tumors, distribution, 2074
spontaneous, intraocular concomitant immunity, 2587
Methotrexate, thymidine and, effect on natural killer function, 1619
Methylcholanthrene, sarcoma Meth A, vaccine, cyclophosphamide and, 2601
Mitogen
B cell stimulation, inhibition, serine protease and, 2494
B lymphocytes activated by, B lymphocyte-associated antigen (B4) expression on, 244
cell proliferation induced by, bursectomy and incubation, 120
lymphocyte blastogenesis and, mast cell granule effects, 1942
lymphocyte proliferation induced by, inhibition by ouabain, 1433
lymphocyte transformation induced by, inhibition, fatty acids and, 1011
Mycoplasma arthritidis, γ-interferon induction by, 2392
Mycoplasma arthritidis-derived, T cell proliferative responses to, 1702
pokeweed, *see* Pokeweed mitogen
T and B cell responses stimulated by, accessory cell phenotype, 2282
T cell subsets stimulated by, interleukin 2 production, 2864
Mitogenesis, T cell, inhibition, calmodulin antagonists, 2291
Mixed lymphocyte reaction, stimulatory ability, mature myelomonocytic cells, 736
MM antigen, cytotoxic T lymphocyte specific for, generation, somatic tumor hybrid, 2059
Monoclonal antibody
anti-HLA.DR, γ-interferon induction by mycoplasma mitogen, 2392
anti-HLA-DR, syngeneic anti-idiotypes against, 1339
anti-idiotype
anti-α1→3 dextran response to, 1375
reovirus receptor identification, 2533
anti-IgM and anti-IgD, effect on B cell proliferation and differentiation, 1306
anti-leukocyte, Fc receptor blockade by, 140
anti-parasite and anti-red blood cell, *Plasmodium falciparum* malaria, 2000
anti-sheep red blood cell, antigen regulation of B cell chronic lymphocytic leukemia, 2046
anti-T cell, macrophage chemiluminescence induced by, 2500
B lymphocytes, generation and characterization, 1754
bovine insulin, idiotypes, 2882
competitive binding assays and, antigenic structure of HLA-A2, 856
cooperative interactions, 1906
differentiation antigens recognized by, 334, 1032
feline leukemia virus envelope gp70, subgroups B and C, 3042
fetal hematopoietic ontogeny analyzed using, 232
functionally distinct epitopes of T-200, blockade of natural killer cell lysis, 1742
GK1.5
antigen-specific proliferation, lymphokine release, and T lymphocyte binding blocked by, 2178
T cell molecule L3T4 identified by, 2445
glycophorin A, erythrocytes, 864
glycoprotein T-200, natural killer cytolytic "trigger," 1149
granulocyte surface molecules identified by, 1882
hemagglutinating, antigen expression by bladder carcinoma cells, 3073
H-2K^b-specific, clonal analysis of H-2K^b + TNP recognition by T cells, 1073
HLA class I- and class II-specific, lymphoproliferation blocking with, 2734
human chorionic gonadotropin, increased affinity, circular antibody-antigen complex and, 1900
IgE anti-dinitrophenyl, IgE-mediated contact hypersensitivity, 1096
IgG1, IgG2a, and IgG2b, fragmentation, 2894
IgMκ, association of κIIIb light chains with, 1322
IgM and all IgG isotypes, cell-mediated lysis of tumor target, 1028
immune regulation by, enhancement and opsonization, skin allografts, 86
interleukin 2, production and characterization, 1808
Leishmania mexicana, protection against, 1616
Leishmania tropica, stage- and species-specific determinants, 1987
leukemia virus gp70, T lymphoma surface molecule recognition, anti-immunoglobulin and, 1576
39,000 m.w. molecule detected by, B lymphocytes and chronic lymphocytic leukemia cells, 3064
natural, reaction with self antigens, hybridomas secreting, 2267
OKT3, interleukin 2 production induced by, OKT8 regulation, 2356
OKT4
SB-specific proliferation blocking, 152
suppressor and helper T lymphocyte subsets, newborns, 1765
OKT8
antigen recognized by, expression by T cells and natural killer and killer cells, 223
interleukin 2 regulation, 2356
sex steroid receptors, 2766
pan-T (anti-Leu-4), T lymphocyte proliferation induced by, 158
Plasmodium gallinaceum, blocking by, 2557
p31 on non-small cell lung cancer, 497
Qa-m7 and Qa-m8 defined by, 546
streptococcal group A carbohydrate, 1326
suppressor cell definition by, 175
Tε and Tγ cells, characterization by, atopia, 2772
T cell proliferation, inhibition by, 1056
T cell-specific determinant recognition, blocking of suppressor T cells and, 1646
T cell suppressor factor, 1843
T helper cell-specific, blocking of autologous mixed lymphocyte reaction, 2323
Thy-1.2 and actin, serologic relatedness, 1332
thyroglobulin, idiotypic cross-reactivity among, 2452
Monocyte
antigen presentation by, stimulant processing and interleukin 1 requirement, 1160
B and non-B lymphocytes and, unique Fc, of, 378
B lymphocyte stimulation independent of, phorbol myristate acetate, 2279
cell lineage, anti-Leu-3/T4 antibodies reacting with, 212
cytotoxicity, activation, immune interferon, 2821
decreased Fc receptor and degradative function of, systemic lupus erythematosus, 217
Fc receptors, hemolytic anemia and, 1240
function, T cell proliferation and, 158
immunoregulatory and effector functions, schistosomiasis, 954
impaired regulation of Epstein Barr virus transformation in rheumatoid arthritis, role in, 768
Leishmania donovani, survival, 1994
lymphokine-stimulated, hydrogen peroxide production by, 2853
macrophages derived from, receptor, endocytosis mediated by, 2368
peripheral blood, prostaglandin E synthesis induced by tumor cells, 445
procoagulant activity, instructor cell Leu-3a$^+$ for, 749
subsets, antibody-dependent cellular cytotoxicity function of, 1780
U397, surface antigens of, 743
Monokine, soluble, requirement for antigen-induced T cell activation, 23
Mononuclear cell
histamine receptor-bearing, functional characteristics, 1854
peripheral blood, lack of pokeweed mitogen-induced IgE formation, 3001
polymorphonuclear cells and, chemotactic activity of epidermal cell-derived thymocyte-activating factor, 816
Motility, leukocyte, parameters, 940
mRNA
γ-specific, B cell differentiation factors, 3049
splenic, immunoglobulin κ-light chain allotypes, 1000
Mucosa, chronic inflammatory disease, sensitization to epithelial antigens, 2796
Multiple sclerosis, peripheral blood lymphocytes, oligoclonal cerebrospinal fluid IgG production, 2328
Mutant
8.6.1, HLA-A2 antigen structural analysis, 2935
bm13, multiple H-2 molecules of D^b and D^{bm13} regions, 1080
Escherichia coli, use as lymphocyte markers, 1189
H-2K^b, influenza-specific cytotoxic T lymphocytes, cross-reactivity patterns, 471
H-2K^{bm}, clonal analysis of H-2K^b + TNP recognition by T cells, 1073
HLA-A2 target cells, cytotoxic T lymphocyte recognition of, 1312
I-A, antibody recognition of, 359
lymphoblastoid cell line, dissociation of DR and MB/MT expressions, 1318
Mutation, recombination and, class II histocompatibility genes, 3052
Myasthenia gravis, peripheral lymphocyte subsets in, thymectomy effects, 773
Mycobacteria, killing by activated macrophages, resistance, 1452
Mycobacterium bovis, genetically controlled host resistance to, cellular mechanisms, 1966
Mycoplasma arthritidis
mitogen, γ-interferon induced by, 2392
mitogen derived from, T cell proliferative responses to, 1702
soluble factor derived from, genetically restricted polyclonal T cell activator, 543
Myeloid cell, Ia and H-2 antigen induction, γ-interferon-induced, 788
Myeloma
idiotype-specific suppression of, accessory cell role, 1728
IgE protein, antibodies to, idiotypic determinant detection by, 3001
γ3 protein, allotypic marker Gm(st), 1865
Myelomonocytic cell, mature, mixed lymphocyte reaction stimulatory ability of, 736

Natural cytotoxic cell, lysis mediated by, somatic cell hybrids sensitive to, 1154
Natural killer cell
activated killer cells and, teratocarcinoma targets distinguishing, 1007
activity and proliferation induction in lymphocytes, mature myelomonocytic cells, 736
activity during lymphatic regeneration, 658
activity inhibition
lipoxygenase antagonists, 2953
lysosomotropic agents and, 125
antibody-dependent cellular cytotoxicity and, inhibition by lipomodulin, 662
augmentation of activity, toxoplasma sonicates and, 458
cytolytic reaction sequence, "trigger" stage, glycoprotein T-200 monoclonal antibody, 1149
cytoskeleton, polarization, target cell conjugation and, 2695
cytotoxic cell lines similar to, growth requirements, 2386
cytotoxicity, nonoxidative mechanism, 1784
cytotoxic T lymphocytes derived from, activation, 1734
depletion, viral infections and, 1531
elevated cytotoxicity, interferon and, persistent viral infection, 991
function, methotrexate and thymidine effects on, 1619
herpes simplex virus-infected cells, lysis by, 2011
interaction with target, recognition structures, 2404
interferon therapy, activity after, 503
killer cells and, expression of antigen recognized by antibody OKT8, 223

Natural killer cell—*continued*
large granular lymphocytes, tumor cell clearance, anti-asialo GM_1 and, 1024
lethal hit, protease-sensitive structures, target cell lysis and, 2705
lysis
blockade, functionally distinct epitopes of T-200 and, 1742
interferon-treated virus-infected cells, 783
mediation by, somatic cell hybrids sensitive to, 1154
phenotype, lung, 2699
severe combined immunodeficiency, 2332
subset definition, Leu-7 and Leu-11 antigens, 1789
suppressive effect, pokeweed mitogen-induced B cell differentiation, 651
Thy-1.2 homologue-positive cells distinct from, vaccinia-induced peritoneal exudate cytotoxicity mediated by, 2545
turnover, viral infection and, 131
virus-specific activity, interferon and, 1849
Natural killer-like cell, interleukin 2 induction of γ-interferon production , participation in, 288
Neisseria gonorrhoeae, serum-resistant and -sensitive, bacterial resistance to complement-mediated killing, 1443
Neonate
anti-δ antibody treatment, effects on immune system, 593, 601
B lymphocyte lineage cells, regulatory disorders, 2219
cord blood lymphocytes, T cell lymphoma virus infection, cell surface antigen expression, 2021
OKT4-defined T lymphocyte subset, suppressor and helper activity, 1765
spleen cell injection, clonal analysis of T cell tolerance, 2165
spleen cell products, resistance to Toxoplasma, 1527
tolerance-inducing capacities, H-2 antigens, 1670
tolerance to H-2, cellular mechanism, 1676
Neoplasm
B lymphocyte, detection and destruction, antibodies against light chain idiotypes, 3058
complement receptor expression by, 899
mammary cell cultures, IgA elaboration in, 869
Nephritis, autoimmune tubulointerstitial, anti-idiotype in, 1268
Nephropathy, IgA, lymphocyte Fcα receptor in, 1246
Neurotoxin, eosinophil-derived, major basic and eosinophil cationic proteins and, 2977
Neutropenia, anti-neutrophil antibody-induced, effect on late phase reactions, 929
Neutrophil
chemiluminescence, luminol-dependent, inhibition by polyanions, 2515
lymphocyte surface-bound immune complex and, interaction, 207
Trypanosoma cruzi, interactions with, 1504
Newborn, *see* Neonate
Nonparenchymal cell, hepatic, abnormal immune complex binding to, 2784
Nucleoside, ricin A and, conjugate, selective inhibition of anti-nucleoside antibody by, 1762
NZB cells, tolerance to γ-globulin prevented by, 1121

OKT8$^+$ cell, interleukin 2 proliferation in, OKT8 antibody inhibiting, 2356
Oligomer, IgE, endocytosis of, 388
Oligosaccharide, invariant chain, association with Ia antigens, 352
Ontogeny
fetal hematopoietic, analysis with monoclonal antibodies, 232
hemopoietic cell, dual embryonic origin, 2262
interleukin 2-responsive cells, fetal thymus, 533
major histocompatibility complex antigens, trophoblast cells, pregnancy, 2348
terminal deoxynucleotidyl transferase expression, thymus, 195
Opsonization, monoclonal alloantibodies, skin allografts and, 86
Ouabain, inhibition of mitogen-induced lymphocyte proliferation by, interleukin 2 and, 1433
Oxidation, cytotoxic T lymphocytes, sodium periodate and, 1426
Oxidative metabolism, monocyte/macrophage, anti-T cell monoclonal antibody-induced, 2500

Pathway
classical, surface modulation of activation, 403
regulation on pneumococci, 409
P388D1 cell, antigen-presenting ability, γ-interferon-mediated induction, 2814
Peanut agglutinin, receptors for, B cell memory transfer, lymph node cell fractionation and, 2254
Peptide
antigen, antigenic strength and memory, distinguishable sites affecting, 319
C3a, immune response suppression by, 2258
complement-derived, cathepsin H, 397
tryptic, disparity, Ia.3,5 antigens, 845
Peritoneal exudate cell
macrophages, T cell activation and, 2714
vaccinia-induced, cytotoxicity, Thy-1.2 homologue-positive cells mediating, 2545
Peritoneum, macrophages, *Ity* gene expression, 3006
Peroxidase, mononuclear leukocytes positive for, dendritic reticulum cell precursors, 2719
Persisting cell, precursor, mast cells and, 923
Peyer's patch, oral antigen, immune responses and secretory antibody production, 2616
Phagocyte
mononuclear
sequential activation for tumor cytolysis, 1038
tumor cell binding by, 2086
Phenol sulfuric test active peak, schistosome antigen, clearance, schistosomiasis, 2520
Phenotype
accessory cell, L-leucine methyl ester sensitivity, 2282
anti-phosphorylcholine response, allotype-linked gene, 1570
cell surface, suppressor T cell, 175
Lyt-2, thymus organ cultures, 1085
natural killer cells, lung, 2699
precursor, cytotoxic and suppressor T lineages, subdivision, 2296
Thy and Lyt, T lymphocyte, immunoregulation in disseminated histoplasmosis and, 984
Phorbol ester, 12-*O*-tetradecanoylphorbol-13-acetate, thymocyte differentiation induced by, 201
Phorbol myristate acetate, B lymphocyte stimulation, monocyte-independent, 2279
Phosphocholine
idiotype-isotype expression, asymmetry in response, 2468
sites binding, C-reactive protein, localization, 2411
Phospholipid
methylation, B cell differentiation factor-stimulated B cell line, 1961
vesicles, binding of cyclosporine by, 712
Phosphorylcholine
binding by non-immunoglobulin molecules, B cells, 365
response phenotype, allotype-linked gene, 1570
Photobleaching, T-independent antigen mobility, antibody-bearing liposomes and, 2924
Phytohemagglutinin
B cell differentiation induced by, T cell suppression of, 1214
depressed spleen cell responses to, interleukin 2 deficiency in Leishmaniasis donovani, 1487
Mycoplasma arthritidis mitogen and, γ-interferon induced by, 2392
responsiveness of thymocytes, interleukin 1 and phorbol ester effects, 201
Picrylchloride, T cells sensitized by, trinitrophenyl-specific immunoregulatory molecules, 2859
Plasma, fibronectin, binding to C1q, 1400
Plasmacytoma-173, mineral oil-induced, lactate dehydrogenase B and, immune response gene separation, 2919
Plasma membrane
complement channel elimination from, temperature dependence of elimination rate, 1411
depolarization, receptor cross-linking, B cell activation, 2641
Plasmodium berghei, malaria-specific cultured T cells and, prevention of cerebral malaria, 1522
Plasmodium falciparum, malaria, monoclonal antibodies to, 2000
Plasmodium gallinaceum, gametes, monoclonal antibodies blocking transmission, 2557
Platelet, activation, selective inhibition, serum amyloid P-component, 1416
Platelet-activating factor
1-*O*-alkyl-2-acetyl-*sn*-glyceryl-3-phosphorylcholine, release from mast cells, 2958
antibody-mediated pneumonitis and, 1802
release, endothelial cells, 2397
Pneumococci, C3b bound to, interaction with factor H, factor I, and properdin factor B, 409
Pneumonitis, antibody-mediated, platelet activating factor and, 1802
Pokeweed mitogen
B cell differentiation induced by, suppression by natural killer cells, 651
IgE formation induced by, lack of, peripheral blood mononuclear cells, 3001
Pollen, ragweed, allergen, isolation and properties, 706
Polyanion, luminol-dependent neutrophil chemiluminescence, inhibition by, 2515
Polymorphonuclear cell
Chagas' disease and, neutrophil interactions with *Trypanosoma cruzi*, 1504
mononuclear cells and, chemotactic activity of epidermal cell-derived thymocyte-activating factor, 816
Polypeptide
Treponema pallidum, humoral immune response in experimental syphilis, 1973
vasoactive intestinal, specific binding sites on peripheral blood lymphocytes, 1173
Polysaccharide
IgA response, lymphokine activation, 2210
pneumococcal, type III, suppressor T cell specificity, cyclophosphamide and, 2190
Pre-B cell, bone marrow, cytoplasmic μ-chain-bearing cells, 2635
Precursor
B lymphocyte
long-term bone marrow cultures, 2240
phenotypic and functional characterization, fetus and adult, 572
C1s, C1 activation measurement and, 1924
cytotoxic, cyclophosphamide-resistant, expansion by interleukin 2, 806
cytotoxic T cell, frequency during lymphatic regeneration, 548
cytotoxic T lymphocyte, requirement for metabolically active stimulator cells, 520
cytotoxic T lymphocytes, frequency, aging, 2215
dendritic reticulum cell, peroxidase-positive mononuclear leukocytes, 2719
lymphoid, dual embryonic origin, 2262
Lyt-2$^-$, interleukin 2 secretion, 2864
macrophage, colony-stimulating factor, interferon-enhanced responsiveness, 2374
mast cell, frequency in normal tissue, 923
phenotypically distinct, cytotoxic and suppressor T lineages, subdivision, 2296
resting, signals required for cytolytic T lymphocyte generation, 606
T cell
clonal abortion of, 1688
Lyt-2-positive, T cell growth factor-reactive T cells and, 19
Pregnancy
allogeneic, alloantigen-specific suppressor T cells induced by, 638
decidual suppressor cells in, 540
major histocompatibility complex antigen, ontogeny, trophoblast cells, 2348
Presidential address, B cell differentiation, molecular aspects, i
Primed lymphocyte test, nonspecific proliferative responses in, antigen-specific secondary response simulation, 165
Procoagulant activity, monocyte, instructor cell Leu-3a$^+$ for, 749
Proenzyme, C1s, C1 activation measurement and, 1924
Progenitor cell, multipotential, erythroid and granulocyte-macrophage, γ, α, and β interferon comparison, 1300
Prostaglandin, macrophage and, natural killer-derived cytotoxic T lymphocytes, activation, 1734
Prostaglandin E
rheumatoid arthritis lymphocytes sensitive to, impaired regulation of Epstein Barr virus transformation in, 768
synthesis induced by erythromyeloid tumor cells, peripheral blood monocytes, 445
Protease
inhibition, natural killer lethal hit, 2705
Schistosoma mansoni, eosinophil activity enhancement by, 464
serine, inhibitor, B cell stimulation inhibited by, 2494

structures sensitive to, target cell lysis, natural killer cell lethal hit, 2705
Protein
acute phase, control of lipopolysaccharide-high-density lipoprotein binding by, 1913
Bence Jones SUT, λVI light chain, region sequence, 2490
C4, secretion, 2420
cationic, eosinophil granule, 2977
C4-binding, genetic polymorphism, 1565
cell surface, acquisition during intrathymic T cell maturation, 1195
C-reactive
antigenicity, lymphocytes, 2930
biosynthesis, 2416
phosphocholine-binding sites on, 2411
HLA, rapid turnover in quiescent lymphocytes, 341
(4-hydroxy-3-nitrophenyl)acetyl-coupled, absence of hapten-specific delayed-type hypersensitivity to, 70
IgE myeloma, antibodies to, idiotypic determinant detection by, 3001
liver-derived inhibitory, arginase activity, 2427
lymphocyte membrane, detergent-insoluble lymphocyte cytoskeletal matrix and, 1917
major basic, eosinophil granule, 2977
myelin basic
B cell determinant of, 275
determinants of, autoimmune encephalomyelitis vaccination specific for, 2810
interaction with macrophage, experimental allergic encephalomyelitis and, 1263
γ3 myeloma, allotypic marker Gm(st), 1865
p22,28 complex, internalization by T cells, 536
phospholipase inhibitory, inhibition of natural killer and antibody-dependent cellular cytotoxicity activities by lipomodulin, 662
p53 transformation-related, variation in antigenic determinants, 329
retinal, experimental autoimmune uveitis, 259
sex-limited, variations in glycosylation of, 1405
surface, Tp50, two functionally distinct epitopes of, 180
tobacco mosaic virus, antibody response to antigenic determinant, 2875
viral, humoral antibody response, cytomegalovirus, 3032
Proteolysis, limited, I-J expression enhanced by, 1380
Pseudomonas aeruginosa, active and passive immunity against, ribosomal vaccine and antiserum, 1

Rabies virus, *see* Virus
Ragweed, pollen allergen, isolation and properties, 706
Receptor
basophil, dissociation of IgE from, 1949
B lymphocyte, interferon-α/β induction, 1895
C3b, expression by T lymphocytes, 684
complement, expression, normal and neoplastic cells, 899
cross-linking, thymus-dependent and -independent antigens, B cell activation, 2641
Fc
blockade, anti-leukocyte antibodies, 140
IgE and IgG, T cells bearing, 2772
monocyte, hemolytic anemia, 1240
monocyte, systemic lupus erythematosus and, 217
T cell hybridomas expressing, different isotypes, 303
Fcα, IgA deficiency and nephropathy, 1246
Fc_γ, monocytes and B and non-B lymphocytes, 378
histamine, mononuclear cells bearing, 1854
insulin, B cell, T cell cooperation for genesis of, 644
interleukin 2
blockade by anti-Tac antibody, 690
expression by HNK-1$^+$ granular lymphocytes, 1822
macrophage, endocytosis mediated by, 2368
peanut agglutinin, lymph node cell fractionation and, B cell memory transfer, 2254
reovirus, idiotypic, 2533, 2539
rosette, lymphocyte cytoskeleton and, 1126
sex steroid, peripheral T cells, 2767
turnover, effect, endocytosis of IgE oligomers and, 388
vasoactive intestinal polypeptide, peripheral blood lymphocytes, 1173
Recombination, mutation and, class II histocompatibility genes, 3052
Reovirus, cell receptors for, monoclonal anti-idiotypic antibody identifying, 2533, 2539
Respiration, responses to leukotrienes and biogenic amines, hyperreactivity, 434
Retina, proteins, experimental autoimmune uveitis, 259
Retrovirus, *see* Virus
Rheumatoid arthritis, lymphocytes, impaired regulation of Epstein Barr virus transformation in, 768
Rheumatoid factor, autoantibodies, cross-reactive anti-idiotypes to, 719
Ribosome, vaccine, immunity to *Pseudomonas aeruginosa* with, 1
Ricin A
antibody and, hybrid, target cell killing, 3091
nucleoside and, conjugate, selective inhibition of anti-nucleoside antibody by, 1762
RNA, synthesis inhibition, deoxyadenosine plus deoxycoformycin, 2761
Rosette, receptor, lymphocyte cytoskeleton and, 1126

Salmonella typhimurium
resistance to, genetic control, 3006, 3014
susceptibility to, genetic control, 2613
Sarcoma, Meth A, vaccine, serologic response, 2601
Schistosoma mansoni
antigens, T cell-dependent, lymphokine-mediated macrophage activation, 1481
congenital athymia and, immunologic response, 1466, 1475
liver granulomas
angiotensins in, 2529
mast cell density, 959
major histocompatibility complex antigens, 962
proteases, eosinophil activity enhancement by, 464
protective immunity against, mast cells and IgE antibodies, 1460
Schistosomiasis
antigen, phenol sulfuric test active peak, clearance, 2520
monocyte immunoregulatory and effector functions, 954
resistance to, macrophage activation and, 948
Schistosomiasis japonica, suppressor T cells, Leu-2a$^+$3a$^-$, 2524
Scrapie, Creutzfeldt-Jakob disease and, genetic control of, 491
Secretion
excretion and, *Giardia lamblia*, 2004
immunoglobulin
bursectomy and incubation, 120
T cell factor-mediated suppression by, 298
interleukin, cytotoxic T lymphocyte hybridomas capable of, 50
Self antigen, monoclonal antibodies reacting to, hybridomas secreting, 2267
Serine esterase, activation, B cell differentiation factor-stimulated B cell line, 1961
Serine protease, inhibitor, B cell stimulation inhibited by, 2494
Serology, tissue lesions and, immunization with *Streptococcus mutans*, 3021
Serum
amyloid P-component, inhibition of platelet activation by, 1416
leukemic, fatty acids and lymphocyte transformation in, 1011
Sinus, subscapular, immune complex transport from, lymph node follicles and, 1714
Skin, allograft, monoclonal antibodies and, 86
Small cell lung cancer, non-small cell lung cancer and, monoclonal antibodies distinguishing, 497
Sodium periodate, cytotoxic T lymphocytes modified by, antigen-nonspecific cytotoxicity, 1426
Soluble factor, *Mycoplasma arthritidis*, genetically restricted polyclonal T cell activator, 543
Somatic cell
hybrids, sensitivity to natural killer and natural cytotoxic cell lysis, 1154
tumor hybrid, cytotoxic T lymphocyte generation, 2059
Spinal cord, T lymphocyte subsets, allergic encephalomyelitis, 2805
Spleen
B cells, viral antigen display by, 3078
cytotoxic T lymphocytes in host, graft-*vs*-host reaction-associated immunosuppression and, 1142
macrophages, *Ity* gene expression, 3006, 3014
mRNA, immunoglobulin κ-light chain allotypes, 1000
suppressor cells, fractionated total lymphoid irradiation, 1108
thymus leukemia-bearing cells, expression, total lymphoid irradiation and, 1683
Spleen cell
antigen and I-J determinant recognition, polysaccharide-specific T cells, cyclophosphamide and, 2190
concanavalin A-stimulated culture, cytotoxic polymorphonuclear leukocytes induced by, 2508
resistance to Toxoplasma infection, neonatal, 1527
responses to phytohemagglutinin, depressed, interleukin 2 deficiency in Leishmaniasis donovani, 1487
suppression mediated by, chronic *Trypanosoma cruzi* infection, 1978
T cell tolerance induced by, neonatal injection, 2165
Splenocyte, thymocyte and, Ia antigen comparison, 1386
Steroid, sex, receptor, peripheral T cells, 2767
Stimulant, presentation by monocytes, processing, interleukin 1 requirement and, 1160
Stimulator cell, metabolically active, cytotoxic T lymphocyte precursors requiring, 520
Streptococcus mutans, immunization with, serology and tissue lesions, 3021
Substance P, T lymphocyte stimulation by, 1613
Sunlight, immunological effects, 171
Superoxide anion, production, acetylated cytochrome *c* detecting, 2104
Suppression
anti-δ, B cell function in, 593
antigen-specific, collagen-induced arthritis, 2995
antitumor immune response, continuous T cell line and, 514
cell-mediated, mucosal IgA response, 115
clonal, hapten-induced cytotoxic T cell tolerance, 2662
delayed-type hypersensitivity, intracamerally induced, 2670
idiotype, polyvalent epitope effects on, 13
immune, accessory cells in, 1728
immune response, synthetic C3a peptides, 2258
immunoglobulin synthesis, B cell line, 298
lymphocyte responsiveness, tumor-derived cells and, 3085
macrophage antimicrobial activity, tumor cell product, 384
macrophage tumoricidal capacity and, dissociation between, 1707
natural killer cell, pokeweed mitogen-induced B cell differentiation, 651
retrovirus, mechanism, T cell proliferation, 2017
soluble immune response, lymphokine, purification, 2648
spleen cell-mediated, *Trypanosoma cruzi* infection, 1978
T cell, B cell differentiation, 1214
T cell-mediated, suppressor cell induction factor activating, 2307
T cell proliferation
Leu-2$^+$ cell subset, 2757
Lyt-1$^+$,2$^-$ T effector cell induced, 2656
T lymphocyte function, leukotriene B_4, 551
Suppressor cell
activation, T cell interactions in, 2154
activity induction, T cell subset alteration and, sunlight effects, 165
antigen-specific, generation, 1209
anti-self, fetal liver, 45
chronic *Trypanosoma cruzi* infection, 1978
desidual, pregnancy and, 540
Epstein Barr virus-induced defective responses, systemic lupus erythematosus, 1797
fractionated total lymphoid irradiation, 1108
helper cell and, primary mixed lymphocyte response, 1065
induction factor, T cell-mediated suppression and, 2307

Suppressor cell—*continued*
OKT4-defined T lymphocyte subset, newborn, 1765
phenotype, definition by monoclonal antibodies, 175
transplantation tolerance and, 57
Suppressor factor
antigen-specific, purification and biochemistry, 2843
mast cell granule-associated, heparin, lymphocyte blastogenesis and, 1942
T cell, monoclonal antibody to, 1843
Surface antigen
granulocyte, identification by monoclonal antibodies, 1802
identification, procyclic *Trypanosoma rhodesiense*, 454
killer cell, characterization, cellular level, 2340
monoclonal antibodies against, Fc receptor blockade, 140
T cell, functionally relevant, 1350
Trypanosoma cruzi, definition by human antibodies, 972
U937 cells and monocytes, modulation during incubation with T lymphocyte-conditioned medium, 743
unusual expression pattern on peripheral lymphocytes, aging and, 191
Syphilis, humoral immune response, *Treponema pallidum* polypeptides and, 1973
Systemic lupus erythematosus, *see* Lupus erythematosus

Tac antigen, Ia antigen and, *in vivo* stimulated T cells, 731
T4 antigen, presence on normal blood monocytes, U937 cells, 745
Target antigen, *H*-2-restricted cytolytic T lymphocyte, identification by, 2551
Target cell
HLA-A2 mutant, recognition by HLA-A2 cell line, 1312
killing, antibody-toxin hybrid molecules, 3091
lysis, protease-sensitive structures, natural killer cell lethal hit, 2705
natural killer cell cytoskeleton, conjugation with, 2695
T cell
activation, differential accessory cell requirements for, 2714
allo-Ia-reactive cell line, T cell clonal expansion and, 37
alloreactive, lectin-stimulated interleukin 2 release, 1274
antigen-induced activation, clone-specific alloantisera, effects, 2645
antigen Leu-4, processing and translation, 1876
antigen-reactive, processed B lymphoma cell antigen and, 2726
antigens independent of, tolerogenicity and immunogenicity, 2196
antigen-specific, macrophage-dependent activation, 23
antigen-specific macrophage activation, schistosomiasis and, 1481
anti-H-2K^b + TNP, H-2K^{bm} mutant reactivity of, 1073
autoreactive clones, autologous virus-transformed targets and, 186
change from cell-mediated to humoral response, cellular interaction analysis, 1103
class II HLA antigen recognition, T4 molecule involvement, 152
clones, macrophage-activating factor from, 833
clone-specific antisera, antigen-induced T cell activation, 2645
continuous line, antitumor immune response suppression, 514
cooperation, B cell insulin receptor genesis and, 644
cytolytic, minor histocompatibility antigen-specific, 2135
cytotoxic
expression of antigen recognized by antibody OKT8, 223
hapten-induced tolerance, 2662
hapten-specific response, 2184
H-2K^b mutant, 471
maturation within sponge matrix allografts, 617
specificity against vesicular stomatitis virus, 475
defect, severe combined immunodeficiency, 2332
deficiency, listeriosis, cortisone and cyclosporin A effects, 450
differentiation antigen, monoclonal antibodies against, macrophage chemiluminescence induced by, 2500
Epstein Barr virus-induced defective responses, systemic lupus erythematosus, 1797
factor, B cell differentiation induced by, 1306
factor derived from, antibody responses to trinitrophenyl-*Brucella abortus* and -Ficoll, 633
factors derived from, B cell destruction by, 1609
Fc receptors for IgE and IgG, characterization, monoclonal antibodies, 2772
helper
cytotoxic T cell and, activation by herpes simplex virus, 479
delayed-type hypersensitivity and, 77
interaction with suppressor T cell, lactate dehydrogenase B and, 628
Lyt-2$^-$, interleukin 2 secretion, 2864
regulation of isotype expression, 2170
suppressor T cell and, primary mixed lymphocyte response, 1065
suppressor T cell and, transplantation tolerance, 57
helper/inducer, migration, 697
hybrid clone, switching from IgE-suppressive to IgE-potentiating factor, 1090
hybridoma
antigen-specific suppressor factors, 2843
coordinate production of lymphokines by, 794
insulin-specific, fine specificity, 2868
lymphocyte maturation factor and, 1816
macrophage-activating factor produced by, 826
polyclonal T cell activator and, 543
production of IgA binding factor by, 303
self H-2D-responsive, 1656
IgA anti-polysaccharide response dependent on, lymphokine activation, 2210
IgG suppression mediated by, 298
I-J expression, enhancement by limited proteolysis, 1380
immune responses mediated by, viral infection effects on, 30
immunity mediated by, antigen-nonspecific cytotoxicity, 1426
immunoenhancing, tumor, 2576
immunoglobulin-recognizing, influence of heavy chain and major histocompatibility complex, 103
immunoregulatory, viral infection and, 1167
interaction preference with B cell, lack of environmental effect on, 9
in vivo stimulated, Tac and Ia antigens on, 731
Leishmanial antigen-specific, 1496
L3T4, identification, monoclonal antibody GK1.5, 2445
lymphokines derived from
B cell differentiation factors, 3049
coordinate regulation, 293
lymphoma, interleukin 2 and colony-stimulating factors, coordinate synthesis, 293
lymphoma virus, *see* Virus
Ly-1:Qa1$^-$ and Ly-1:Qa1$^+$, suppressor cell activation, 2154
major histocompatibility complex-restricted lines and clones, immune interferon production and proliferation, 1049
malaria-specific, adoptive transfer, prevention of cerebral malaria and, 1522
maturation, intrathymic, p80 acquisition during, 1195
mitogenesis, inhibition, calmodulin antagonists, 2291
mitogen-stimulated response, accessory cell phenotype, 2282
M locus- and Ia-reactive, proliferation, 1056
natural killer-target interaction molecules, 2404
peripheral, sex steroid receptors, 2767
polyclonal, genetically restricted activator, *Mycoplasma arthritidis*, 543
post-thymic, renewal rates, 2158
precursor, clonal abortion of, 1688
proliferation
induction by pan-T antibody, 158
retrovirus suppression of, 2017
proliferative response, Leu-2$^+$ cell subset suppressing, 2757
proliferative responses, *Mycoplasma arthritidis*, accessory cell and, 1702
reaction with anti-Leu-4 antibody, internalization of p22,28 complex by, 536
sensitization to picrylchloride, trinitrophenyl-specific immunoregulatory molecules, 2859
stimulated, differentiation antigens on, 334
subset, mitogen-stimulated, interleukin 2 production, 2864
subset alteration, suppressor T cell activity induction and, sunlight effects, 171
subset deletion, hapten-specific cytotoxic T lymphocyte unresponsiveness, 1663
subset modulation, total lymphoid irradiation and, 1683
suppression, phytohemagglutinin-induced B cell differentiation, 1214
suppression mediated by, suppressor cell induction factor activating, 2307
suppressor
abnormal subsets, systemic lupus erythematosus, 753
alloantigen-specific, allopregnancy and, 638
antibody blocking of, 1646
IgE class-specific, 2751
interaction with helper T cell, lactate dehydrogenase B and, 628
interferon-activated, 2301
Leu-2a$^+$3a$^-$, schistosomiasis japonica, 2524
pneumococcal polysaccharide-specific, cyclophosphamide and, 2190
suppressor and helper
interaction between, lactate dehydrogenase B, 628
primary mixed lymphocyte response, 1065
suppressor/cytotoxic, concanavalin A-stimulated, helper/inducer T cell migration and, 697
suppressor factor, monoclonal antibody to, 1843
surface antigen, functionally relevant, 1350
surface molecules, leukemia virus gp70 monoclonal antibodies and, 1576
surface protein Tp50, two functionally distinct epitopes of, 180
T cell growth factor-reactive, Lyt-2-positive T cell precursors and, 19
thymic atrophy, lymphocyte subsets in myasthenia gravis, 773
transformation, reirovirus, 1611
tumor product, xenoantisera against, cross-reaction with immunoglobulin Fab determinants, 1582
unresponsiveness to alloantigens, spleen cells, clonal analysis, 2165
T effector cell, Lyt-1$^+$,2$^-$, T cell proliferation suppression by, 2656
Teratocarcinoma
antigens, antibodies to, vasectomy sera, 2908
immune properties, natural killer *vs* activated killer cells, 1007
Tetanus toxoid, immunization with, Tac and Ia antigens on, 731
12-*O*-Tetradecanoylphorbol-13-acetate, interleukin 1 and, thymocyte differentiation induced by, 201
Thy-1 antigen, B and T lymphocytes, expression on, 2903
Thy-1.2 antigen
actin and, serologic relatedness, monoclonal antibody and, 1332
expression modification, lipid modulating agents and, 1356
Thy-1.2 homologue, vaccinia-induced peritoneal exudate cytotoxicity, mediation by, 2545
Thymectomy
effects on peripheral lymphocyte subsets, myasthenia gravis, 773
thymosin$_{\alpha_1}$, circadian rhythm, 148
Thymidine, methotrexate and, effect on natural killer function, 1619
Thymocyte
differentiation, interleukin 1- or 12-*O*-tetradecanoylphorbol-13-acetate-induced, 201
differentiation antigens, T6 and M241, 851
medullary, p80 antigen on, 1195
splenocyte and, Ia antigen comparison, 1386
subset generation, Lyt-2 phenotype and cell cycle status, 1085
syngeneic cell-responding, enrichment, subset separation and, macrophage interactions, 2110
Thymocyte-activating factor, epidermal cell-derived, chemotactic activity of, 816
Thymosin$_{\alpha_1}$, circadian rhythm, thymectomy effects, 148
Thymosin β_4, antibodies to, production and characterization, 821

Thymus
antigens dependent on, *see* Antigen
antigens independent of, *see* Antigen
atrophy, lymphocyte subsets in myasthenia gravis, 773
B cell memory development, 567
bone marrow cells homing to, characteristics, 64
dependent and independent antigens, receptor cross-linking, B cell activation, 2641
intact Sm/RNP antigens, isolation, 347
interleukin 2-responsive cells, ontogeny, fetus, 533
leukemia, cells bearing, total lymphoid irradiation and, 1683
leukemia antigen, structural identity of homologues, 1344
organ cultures, Lyt-2 phenotype and cell cycle status of, 1085
post-thymic expansion, T cell, 2158
terminal deoxynucleotidyl transferase expression, ontogeny and development, 195
Thyroglobulin
autoimmune thyroiditis, serum levels, 1252
monoclonal antibodies to, idiotypic cross-reactivity among, 2452
T lymphocyte line specific for, thyroiditis and, 2316
Thyroiditis
autoimmune
serum thyroglobulin levels, 1252
thyroglobulin-specific T lymphocyte line, vaccination, 2316
Tissue, lesions, immunization with *Streptococcus mutans* and, 3021
T lymphoblast, B lymphoblast and, deoxyadenosine production, 1776
T lymphocyte
alloimmunization-induced, graft-*vs*-leukemia activity, 2050
autoimmune encephalomyelitis, determinant-specific vaccination, 2810
B lymphocyte and, Thy-1 antigen on, 2903
C3b receptor expression, characterization, 684
cytolytic
DC-specific, OKT8$^+$, 2777
H-2-restricted, viral antigen identification, 2551
influenza-infected cell recognition by, 1635
interactions with target, cell surface antigens associated with, 611
signals required for generation, 606
cytotoxic
activation by herpes simplex virus, 479
alloreactive, lytic activity modulation, 2141
anti-tumor, activation, 1017
autoreactive, generation, 2128
bifunctional hybridomas, 50
clones specific for class II major histocompatibility complex antigens, 678
generation suppression, 45
graft-*vs*-host reaction-associated immunosuppression, 1142
Gross leukemia virus-associated tumor antigens defined by, 3078
hapten-specific, Ia recognition in generation of, 1650
hapten-specific, unresponsiveness in, 1663
H-2^b mutant, 471
lymphocyte function-associated antigen-1, 1182
modulation, adenosine 3′:5′-monophosphate role, 2945
natural killer alloantigens on, 1391
natural killer-derived, activation, 1734
precursor, frequency, aging, 2215
precursor, frequency during lymphatic regeneration, 548
precursor, metabolically active stimulator cells, 520
QA-1 encoded determinants defined by, 2147
recognition of HLA-A2 mutant target cells, 1312
sodium periodate-modified, antigen-nonspecific cytotoxicity by, 1426
somatic tumor hybrid cells, 2059
specific event associated with lethal hit, 1138
specificity against vesicular stomatitis virus, 475
suppressor and, subdivision, 2296
T antigen fragment recognition, 2580
N-α-tosyl-L-lysyl chloromethylketone and, 2477
cytotoxic and helper, alloantigen effects, eye, 2670
differentiation, p80 antigen on medullary thymocytes, 1195
Fc receptors for IgE and IgG, characterization, monoclonal antibodies, 2772
helper, binding, monoclonal antibody GK1.5 blocking, 2178
immunoregulatory, viral infection and, 1167
Leishmanial antigen-specific, 1496
mast cell density influenced by, liver granuloma, 959
medium conditioned by, U937 cell surface antigen modulation during incubation with, 743
OKT4-defined subset, suppressor and helper activity, newborns, 1765
post-thymic, renewal rates, 2158
proliferation, induction by pan-T antibody, 158
response to cytochrome *c*, 319
specific suppression of function, leukotriene B_4, 551
stimulation, substance P, 1613
subset, experimental allergic encephalomyelitis, 2805
suppressor
cytotoxic and, subdivision, 2296
Leu-2a$^+$3a$^-$, schistosomiasis japonica, 2524
Thy and Lyt phenotypes from, immunoregulation, disseminated histoplasmosis, 984
T lymphoma, cell surface molecules, recognition, 1576
Tobacco mosaic virus, *see* Virus
Tolerance, γ-globulin, prevention by NZB cells, 1121
Tolerogenicity, immunogenicity and, T-independent antigens, 2196
N-α-Tosyl-L-lysyl chloromethylketone, site of action, cytotoxic T lymphocytes, 2477
Toxoplasma, multiplication, neonatal spleen cell products and, 1527
Toxoplasma gondii
antigens, Western Blot analysis, 977
soluble and particulate fractions, natural killer cell activity augmentation by, 458
Transplantation
bone marrow
interleukin 2 and, 1771, 1205
resistance, characterization of effector cells, 92
tolerance
neonatal induction, autoimmunity and immune complex disease after, 251
suppressor cell in, 57
Treponema hyodysenteriae, pathogenicity, lipopolysaccharide involvement in, 997
Treponema pallidum, polypeptides of, humoral immune response in experimental syphilis, 1973
Trinitrobenzene sulfonic acid, treatment with, functional deletion of T cell subsets required for, 1663
Trinitrophenyl
anterior chamber-associated immune deviation, cyclophosphamide-sensitive contrasuppression, 2745
Brucella abortus and Ficoll, antibody responses to, 633
cytotoxic T cell generation specific for, deletion of T cell subsets required for, 1663
cytotoxic T lymphocyte responses specific for, generation, Ia recognition in, 1650
immunoregulatory molecules specific for, characterization, 2859
Trinitrophenyl-Ficoll, lymphokine-induced response, X-linked immunodeficiency, 1698
Trophoblast cell, major histocompatibility complex antigen on, ontogeny, pregnancy, 2348
Trypanosoma cruzi
chronic infection, suppressor cells in, 1978
destruction of amastigote form, neutrophils and, 1504
macrophage susceptibility, modulation, guanosine-3′:5′ cyclic monophosphate, 3028
surface antigen, definition by human antibodies, 972
Trypanosoma rhodesiense, procyclic, surface antigen identification, 454
Trypanosome, surface coat variant antigen, polyclonal lymphocyte activation caused by, 1983
Trypanosomiasis, anti-idiotype-induced immunity, genetic restrictions, 1511
Tumor
antigen, liposomes as membrane-like immunogen for, 485
B cell, immunotherapy with anti-idiotypes, 1600
cell-mediated lysis, monoclonal antibodies and, 1028
cells derived from, suppression of lymphocyte responsiveness by, 3085
cytolysis, sequential activation of mononuclear phagocytes for, 1038
immunoenhancing T cells, anti-idiotypic subsets, 2576
leukemia virus-induced, viral antigen identification, cytolytic T lymphocytes, 2551
mammary, tumor-associated macrophages of, 2074, 2079
secondary challenge, intraocular concomitant immunity, 2587
somatic cell, cytotoxic T lymphocyte generation, 2059
T cell, product, xenoantisera against, 1582
virus, immunosuppression induced by, 2595
Tumor antigen
Gross leukemia virus-associated, cell surface expression, 3078
SV40, cytotoxic T lymphocyte recognition of, 2580
Tumor cell
binding, phagocytes, 2086
clearance, natural killer cells and, 1024
erythromyeloid, prostaglandin E synthesis in peripheral blood monocytes, 445
interleukin 2 inhibitors from, 2837
product, macrophage antimicrobial activity suppression by, 384
rejection, natural killer and interferon activity, persistent viral infection, 991
syngeneic, Ly-2$^+$ effectors cytotoxic for, 1017

Urine, light chain idiotypes, antibodies against, neoplastic B lymphocytes, 3058
Uterus, decidua, suppressor cell activity, pregnancy and, 540
Uveitis, experimental autoimmune, retinal antigens in, 259

Vaccination, determinant-specific, autoimmune encephalomyelitis, 2809
Vaccine
rabies virus, antigen-specific antibody response, 1234
ribosomal, immunity to *Pseudomonas aeruginosa* with, 1
sarcoma Meth A, cyclophosphamide pretreatment and, 2601
Vaccinia
intermediate filaments and, cross-reacting antibodies, 1546
peritoneal exudate cells induced by, cytotoxicity, Thy-1.2 homologue-positive cells mediating, 2545
Variant antigen, trypanosomal surface coat, polyclonal lymphocyte activation caused by, 1983
Vasectomy, antisperm antibodies, embryonal teratocarcinoma, 2907
Vesicle, phospholipid, binding of cyclosporine by, 712
Vesicular stomatitis virus, *see* Virus
Virus
cytomegalovirus, immunogenic proteins of, 3032
Epstein Barr
B cell line transformed by, malaria and, 2000
immune responses in systemic lupus erythematosus, 1797
impaired transformation regulation in rheumatoid arthritis, 768
fibroma, immunosuppression caused by, 2595
herpes simplex
activation of helper and cytotoxic T cells by, 479
cells infected with, natural killer cell lysis and, 2011
ocular, B cell depletion and, 1554
herpes simplex 1
interferon-enhanced susceptibility to natural killer lysis, 783
natural killer activity specific for, interferon and, 1849
infection
immunoregulatory T lymphocytes triggered by, 1167
natural killer cell depletion and, 1531
natural killer cell turnover during, 1539

Virus—*continued*
influenza
fine specificity of antibody response, 1229
infection, recognition by cytolytic T lymphocytes, 1635
local infection, pulmonary natural killer cells, 2699
leukemia
accessory cell function failure and, 16
feline, envelope gp70, monoclonal antibodies to, 3042
gp70, monoclonal antibodies to, 1576
Gross, tumor antigens associated with, cell surface expression, 3078
tumor induced by, viral antigen identification, 2551
lymphocyte responses specific for, Aleutian disease, 1558
lymphocytic choriomeningitis, natural killer cells and interferon, 991
Moloney murine leukemia, tolerance to, accessory cell function failure and, 16
rabies, antigen-specific antibody response, 1234
retrovirus
gene expression, lymphocyte activation and, 3036
T cell proliferation suppression, mechanism, 2017
T cell transformation by, interferon production, 1611
targets transformed by, cytotoxic T cell clones directed at, 186
T cell lymphoma, cord blood lymphocytes infected with, antigen expression, 2021
tobacco mosaic, antibody response to antigenic determinant, 2875
vesicular stomatitis
effect on hapten-specific T cell immunity, 30
specificity of cytotoxic T cell clones against, 475

Western Blot analysis, *Toxoplasma gondii* antigens, recognition by IgM and IgG antibodies, 977

Xenoantisera, T cell tumor product, cross-reaction with immunoglobulin Fab determinants, 1582